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The Siah ubiquitin ligases play an important role in a number of 
signaling pathways in cancer progression and metastasis. One such critical 
pathway regulated by Siah2 in cancer is the hypoxia inducible factor 1α (Hif-
1α) dependent pathway, which gets activated in response to hypoxia. The 
domain architecture of Siah2 consist of a ‘really interesting new gene’ (RING) 
domain at its N-terminus, followed by two novel zinc-finger motifs and a 
highly conserved substrate binding domain (SBD) at its C-terminus. The 
substrate binding domain (SBD) of Siah2 is of importance in the induction of 
the Hif-1α dependent pathway by regulating prolyl hydroxylase 3 (PHD3), a 
well-studied substrate of Siah2 under hypoxia. Siah2 is also found to be 
involved in a Hif-1α independent pathway by regulating sprouty2 (SPRY2) via 
the Ras/ERK pathway. Since these pathways are critical in human cancers, 
various studies have suggested that Siah2 may be a suitable target for 
developing inhibitors.  
This study has three aims: the first is to identify specific drug like lead 
molecules towards the SBD of Siah2 using in silico high throughput virtual 
screening (HTVS); the second is to validate the identified compounds using in 
vitro and in vivo binding assays and the third is to identify the critical residues 
involved in Siah2 substrate specificity. 
 Firstly, we prepared a structure of the SBD of Siah2 using a homology 
modeling approach, followed by molecular dynamics simulation in order to 
analyze the stability of the model. Eventually, we applied in silico structure-
based HTVS and identified 5 ligands from the Maybridge database which 
interact with the SBD of Siah2. Menadione, a compound that has earlier been 
identified and characterized as a Siah2 inhibitor was used as a reference ligand 
for screening and selection of lead molecules. 
 Secondly, since Siah2 is a non-catalytic protein, further experimental 
validation was performed targeting protein-protein interaction with partners. 
We experimentally validated the computationally identified potential and 
selective Siah2 inhibitors in vitro and in vivo through binding assays. The 
ix 
results obtained show that the identified drug-like small molecules could 
partially inhibit protein-protein interaction. In addition, the compounds also 
possess anti proliferative and cytotoxic activity.  Furthermore the backbone 
structural scaffold of these inhibitors could serve as building blocks in 
designing suitable drug-like molecules for cancer. 
The unique role of Siah1 and Siah2 is still unclear. Siah1 and Siah2 
have their respective substrates as well as several common substrates. Our 
third study explores the substrate specificity of Siah1 and Siah2. We intend to 
identify the critical region or residues of Siah2 that confer substrate 
specificity. We have identified a few key residues that might play a crucial 
role in the binding of selective Siah2 substrates. Further mutational studies are 
being carried out to identify the specific residues involved in binding. This 
study might help in further understanding of the detailed roles of Siah1 and 
Siah2 and in designing more specific Siah based therapeutic strategies. 
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CHAPTER 1. INTRODUCTION 
 
1.1 Biological background 
1.1.1 The importance of regulated protein degradation 
 In eukaryotes, intracellular protein degradation is a highly selective 
process, whereby proteins are broken down into their constituent amino acids 
at widely differing rates. This selective process impacts a range of cellular 
functions and serves several important homeostatic purposes. For example, 
gene expression patterns and developmental programs can be altered via 
coordinated destruction of transcriptional regulatory proteins (Conaway, 
Brower et al. 2002). Additionally, aberrant proteins that are mutated, damaged, 
or mis-folded and fail to degrade may pose a threat to cellular integrity. This is 
essential in protecting cells against environmental stress. The function and 
dysfunction of protein degradation have been implicated in the pathogenesis of 
many diseases including numerous cancer, neurodegenerative, immunological  
and several other disorders (Schwartz and Ciechanover 1999). Understanding 
the mechanisms involved in this process are therefore important for 
understanding and treating human disease.  
 The intracellular degradation of protein is mainly achieved in two 
ways. First is by a lysosomal pathway, which is normally a non-selective 
process. The second and the major pathway is the ubiquitin proteasome 
pathway (UPP), a selective process which involves three phases. Proteins 
marked for degradation are covalently linked to ubiquitin known as 
Ubiquitination and the polyubiquinated protein is targeted to an ATP-
dependent protease complex, the proteasome, for degradation and the 
ubiquitin is released (termed deubiquitination) and reused. 
 
1.1.2 Ubiquitination and protein degradation 
 Ubiquitin is a highly conserved, small protein of 76 amino acids and 
has a molecular mass of about 8.5 kDa. It acts as a tag for proteins to signal 
degradation, subcellular localization, membrane trafficking, DNA repair and 
chromatin dynamics (Murata, Yashiroda et al. 2009). The key feature of 
ubiquitin includes 7 lysine residues through which it forms a polymer by 
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forming covalent linkages through any one of the lysine residues. 
Polyubiquitin linkages through lys48 and lys63 are well-characterized. The 
substrates with lys48 linkages undergo degradation, whereas Lys63 linked 
chains tend to be directly involved in signal transduction (Thrower, Hoffman 
et al. 2000). The functional consequences of other ubiquitin linkages remain 
unclear, and current research aims to determine how those lysine linkages 
affect the protein substrates.  
 The ubiquitination reaction requires at least three enzymes: an E1 
ubiquitin activating enzyme, an E2 ubiquitin conjugating enzyme, an E3 
ubiquitin ligase that functions in a hierarchical system that allows ubiquitin to 
be activated and become covalently linked to protein substrates (Hershko 
1996; Hershko and Ciechanover 1998). This conjugation process is reversible, 
and ubiquitin is removed from substrates by deubiquitinating enzymes 
(DUBs). An E4 ubiquitin chain assembly factor may be required if the E3 
ubiquitin ligase is unable to polyubiquitinate a protein substrate (Koegl, Hoppe 
et al. 1999). 
 Protein modification by ubiquitin also has non-conventional (non-
degradative) functions that are dictated by the number of ubiquitin units 
attached to proteins (mono versus polyubiquitination). Monoubiquitination is 
the attachment of a single ubiquitin molecule to a substrate and is implicated 
in many cellular functions including protein trafficking between various 
cellular compartments, DNA repair and transcriptional regulation (Hicke and 
Dunn 2003).  Polyubiquitination involves the addition of several ubiquitin 
molecules to the first ubiquitin moiety. These polyubiquitin chains target 
proteins for destruction, by a process known as proteolysis by the multiprotein 
complex 26S proteasome (Fig. 1).  
 The 26S proteasome is a 2.5 MDa complex that is made up of two 
components: a 20S core particle and the 19S regulatory particle (Hanna and 
Finley 2007). The 20S core particle is a barrel-shaped complex that consists of 
seven proteins which are responsible for the peptidolytic activity of the 
proteasome. The 19S component is the regulatory subunit that can be further 
subdivided into two sub complexes the base and the lid. The base aids in 
substrate unfolding prior to degradation and is located proximal to the core 
particle; unfolding of the protein is required since the barrel of the 20S 
3 
proteasome core particle is too small to degrade folded proteins. The lid of the 






Figure 1. The ubiquitin proteolytic pathway. 1: Activation of ubiquitin by 
the ubiquitin-activating enzyme E1, a ubiquitin-carrier protein, E2 (ubiquitin-
conjugating enzyme, UBC), and ATP. The product of this reaction is a high-
energy E2∼ubiquitin thiol ester intermediate. 2: Binding of the protein 
substrate, via a defined recognition motif, to a specific ubiquitin-protein ligase, 
E3. 3: Multiple (n) cycles of conjugation of ubiquitin to the target substrate 
and synthesis of a polyubiquitin chain. E2 transfers the first activated ubiquitin 
moiety directly to the E3-bound substrate, and in following cycles, to 
previously conjugated ubiquitin moiety. Direct transfer of activated ubiquitin 
from E2 to the E3-bound substrate occurs in substrates targeted by RING 
finger E3s. 3′: As in3, but the activated ubiquitin moiety is transferred from E2 
to a high-energy thiol intermediate on E3, before its conjugation to the E3-
bound substrate or to the previously conjugated ubiquitin moiety. This reaction 
is catalyzed by HECT domain E3s. 4: Degradation of the ubiquitin-tagged 
substrate by the 26S proteasome complex with release of short peptides. 5: 
Ubiquitin is recycled via the activity of deubiquitinating enzymes (DUBs). 





1.1.3 E3 ubiquitin ligases  
 The roles of E3 ubiquitin ligases can be broadly characterized as 
substrate recognition and polyubiquitin chain formation with the aid from E2 
enzyme. E3 binds to a substrate via the degron – the ubiquitination signal, 
conferring substrate specificity, and E3 also catalyzes the ligation of one or 
more ubiquitins to the substrate (Pickart 2001) . In the human there are about 
600 E3 ubiquitin ligases. However the detailed molecular mechanisms of 
protein selection are poorly understood and the exact protein substrates for 
each E3 are mostly unknown. 
 Generally, E3 ubiquitin ligases can be classified into three main types 
based on their structure and mechanism of action. These include the HECT 
(homologous to E6-AP carboxy-terminus) domain family, the U-box family 
and the RING (really interesting new gene) finger family (Jackson, Eldridge et 
al. 2000). The HECT domain proteins are large monomeric E3’s which 
contain a cysteine residue that forms a covalent bond with the activated 
ubiquitin before transferring it to the substrate (Scheffner, Nuber et al. 1995). 
The RING and U-box E3 ligases however do not possess an active-site 
cysteine residue and these E3’s simply serve as a scaffold, bringing the E2-
ubiquitin complex and substrate in close proximity to mediate the transfer of 
ubiquitin from the E2 enzyme directly to the substrate. 
 The majority of E3 ubiquitin ligases are members of the RING finger 
family and over 600 human genes encoding RING finger E3s have been 
identified (Deshaies and Joazeiro 2009), The RING finger constitutes a small 
zinc-binding domain that binds to specific E2 enzymes (Lorick, Jensen et al. 
1999; Joazeiro and Weissman 2000). The U-box E3s have a similar tertiary 
structure to that of the RING finger except that the U-box scaffold is stabilised 
by salt-bridges and hydrogen bonds rather than zinc ions (Aravind and Koonin 







1.1.4 The Siah family of proteins 
 SIAH (Seven in Absentia Homolog) is a mammalian homolog of 
Seven in Absentia (SINA), a Drosophlila protein which was the first of the 
family to be defined that has a function in eye development (Carthew and 
Rubin 1990). The Siah family of proteins are evolutionarily conserved E3 
ubiquitin ligases containing an N-terminal RING-finger domain required for 
interaction with E2 ubiquitin conjugating enzymes, and a C-terminal substrate 
binding domain (SBD) which interacts with target proteins (Hu, Chung et al. 
1997). Specific target protein degradation via the ubiquitin–proteasome 
pathway is accomplished through the N-terminal RING domain of Siah 
proteins (Hu and Fearon 1999).  Drosophila SINA was first isolated in a 
screen for mutations which affect the morphology of the Drosophila eye and 
SINA targets the transcriptional repressor, tramtrack 88 (TTK88) for 
degradation by cooperating with phyllopod (PHYL) and is essential for the 
correct development of R7 photoreceptor cells in the compound eye(Carthew, 
Neufeld et al. 1994). Another Drosophilia protein Sina-homologue, SinaH 
(46% identical to SINA) was recently identified (Cooper, Murawsky et al. 
2008). Characterization of murine Sina homologues (Della, Senior et al. 1993) 
revealed that the  mouse genome contains a family of five Siah genes, located 
at unlinked chromosomal positions (Holloway, Della et al. 1997). Two of 
these genes, Siah1-ps1 and Siah1-ps2, are pseudogenes as they contain a 
number of frame shifts and in-frame stop codons within the expected coding 
region. However, the remaining three genes, Siah1a, Siah1b and Siah2 have 
open reading frames and are expressed.    
 In contrast, only two SINA homologues have been identified in the 
human genome, Siah1 and Siah2 (Nemani, Linares-Cruz et al. 1996), both of 













Figure 2. Domain architecture of Siah. (a) Siah 1 domain organization 
containing structurally characterized SBD. (b) Siah2 domain organization 
containing structurally uncharacterized SBD. 
 
 Structurally, the Siah family has a divergent N-terminal domain, and a 
highly conserved C-terminus, SBD that encompasses two Zinc fingers (ZnF) 
(Fig. 2). So far three SBD crystal structure of Siah1 have been solved and 
listed as follows. 
1. The crystal structure of the SBD domain of murine Siah-1a was determined, 
and it shows that the cysteine-rich region forms a pair of zinc fingers and that 
the C-terminal region self-dimerizes. It was found that the SBD adopts eight-
stranded β-sandwich fold that is homologous to tumor necrosis factor (TNF) 
receptor associated factor (TRAF) proteins (Polekhina, House et al. 2002). 
Later studies showed that Siah2, via degradation of TRAF2, was a regulator of 
TRAF2 signaling (Habelhah, Frew et al. 2002). 
 It has been reported that many Siah binding proteins contain a common 
binding motif that may act as a degradation signal. This core sequence, 
PxAxVxP, often referred to as the ‘degron motif’, was found to be conserved 
and functional in a number of Siah-interacting proteins (examples such as SIP, 
TEIG-1, DCC). Other Siah interacting proteins, including KID, APC, 
synphylin-1, carry similar peptides that do not perfectly match the reported 
consensus degron motif (Dinkel, Michael et al. 2011). High affinity peptides 
derived from phyllopod and plectin have been shown to bind very strongly to 
Siah1 with a Kd  of ~100 nM and to compete effectively with a range of Siah-
binding proteins, including SIP (House, Frew et al. 2003) 
2. The crystal structure of SBD of human Siah1 bound to a degron motif 
containing peptide from SIP, was determined (Santelli, Leone et al. 2005). The 
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peptide binds to SBD with a kd of 24 ± 4µM. This study reported two acid 
patches on SBD of Siah1 which includes the residues Glu161, Asp162, 
Glu226 and Glu237 in the shallow groove, forms salt bridges with SIP 
peptide.  
3. The crystal structure of SBD of human Siah1 bound to a degron motif-
containing peptide from PHYL was determined and reveals a binding site for 
Siah-interacting proteins (House, Hancock et al. 2006). This site is distinct 
from those previously hypothesized as protein interaction sites. Various 
interacting residues that interact with the peptide were identified. Some 
residues that are reported to bind to the peptide includes, Thr156, Leu158,  
Asp162, Val164, Phe165, Leu166, Thr168, Ala175, Trp178, Asp177, Met180 
and Asn276. Further mutations of the Siah1 residues that interact with the 
degron motif abrogate binding to the peptide. Mutations were performed based 
on the crystal structure of the SBD-peptide complex as a guide. Mutation of 
Met180Lys in the hydrophobic pocket abolished the binding of the target to a 
greater extent by Siah underlying the importance of the hydrophobic 
interaction observed in the crystal structure, and suggesting that it is a key 
recognition point. However other mutations in strands β0 and β1 do not have 
any pronounced effect as Met180. 
 These Siah structures reveal a fold that has not been seen in other E3 
structures (Schulman, Carrano et al. 2000; Zheng, Wang et al. 2000). To date 
no crystal structure of Siah2 has been determined although both Siah1 and 
Siah2 are expected to have a similar fold because of high sequence similarity. 













1.1.6 Diverse role and substrates of Siah 
 The  Drosophila version of this protein, Sina is required for targeting 
the TTK88 for degradation , an essential process for neuronal differentiation 
of R7 photoreceptor cells in the developing fly eye (Tang, Neufeld et al. 
1997). In mammals the substrates targeted for degradation are quite diverse. 
The role of the RING finger E3 ubiquitin ligase Siah is implicated in the 
control of diverse cellular biological events. The Siah proteins regulate 
ubiquitination-dependent degradation of multiple substrates, including 
transcriptional repressors NcoR/TIEG-1, activators β-catenin, netrin receptor, 
a microtuble-associated motor protein (Kid), TRAF2, OGDC-E2, PHD3, 
SPRY2, HIPK2, Nrf2, DCC and other proteins thus inﬂuencing an array of 
regulatory functions such as angiogenesis, DNA damage response, 
mitochondrial dynamics and Ras- and estrogen-receptor (ER) signaling (Fig. 
3).   More than 30 substrates of the Siah ubiquitin ligases have been identified 
to date and have been reviewed (Nakayama, Qi et al. 2009; Qi, Kim et al. 
2013). It can directly mediate or bind to adaptor proteins to mediate 
degradation. For example, substrates such as transforming growth factor beta 
TGFβ, interacts directly with Siah (Johnsen, Subramaniam et al. 2002) 
whereas the interaction with substrates such as β-catenin and TTK88 are 
mediated through the adaptor proteins SIP/APC and PHYL (Matsuzawa and 
Reed 2001). As described earlier, SIP and PHYL peptides engage the human 
Siah SBD in a near identical manner with an apparent 100-fold higher affinity 
for the PHYL degron peptide than the SIP degron peptide (Santelli, Leone et 
al. 2005; House, Hancock et al. 2006).  
 In addition to substrate ubiquitination, Siah1 and Siah2 can also self or 
auto-regulate their own stability in the presence of an E2 enzyme, a property 
that may be used as an auto-regulatory mechanism to control its own 
intracellular levels (Hu and Fearon 1999; Depaux, Regnier-Ricard et al. 2006). 
Siah2 mutant mice under normal conditions are fertile and phenotypically 
normal whereas Siah2 mutants under stress conditions show marked 
phenotypes,  suggesting central role for it in maintaining normal cellular 
homeostasis and response to stress (Frew, Hammond et al. 2003). It is 
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interesting to note that most signaling pathways regulated by Siah2 are 





Figure 3. Outline of Siah regulation and function. Factors involved in the 
regulation of Siah ligases are associated with stress response, including 
hypoxia, ER stress and genotoxic stress, which induce respective transcription 
factors, microRNA to induce Siah2 transcription, as well as post-translational 
modifications that determine Siah subcellular localization and activity. 
Consequently, Siah activities as an E3 ubiquitin ligase affects growing number 
of substrates associated with fundamental cellular processes including 








1.1.7 Siah1 and cancer 
 Studies revealed that Siah1 plays an important role in regulating cell 
proliferation and cell apoptosis. Role of Siah1 in cancer is poorly understood. 
In this regard, most of the studies point Siah1 towards tumor suppressive role 
in contrast to oncogenic role of Siah2.  Some of the early studies have reported 
Siah1 as a tumor suppressor that causes growth arrest or has pro-apoptotic 
properties (Matsuzawa, Takayama et al. 1998).  It is also involved in the 
degradation of the oncogene β-catenin, via interactions with adenomatous 
polyposis coli (APC) (Liu, Stevens et al. 2001) and Siah-interacting protein 
(SIP) (Matsuzawa and Reed 2001) . So far there is only limited evidence to 
support this role 
 The expression levels of Siah1 are reported to be reduced or down 
regulated in various cancers. Also inhibition or low levels of Siah1 has been 
shown to reduce apoptosis, thereby promoting cancer progression (Kim, Cho 
et al. 2004; Brauckhoff, Ehemann et al. 2007; Yoshibayashi, Okabe et al. 
2007; Wen, Yang et al. 2010).  
 
1.1.8 Role of Siah2 in cancer 
 In contrast to the role of Siah1 in cancer, Siah2 in cancer is well 
characterized. Growing evidences highlight the functional role and supporting 
inhibition studies of Siah2 in the progression of multiple types of cancer, 
including breast (Sarkar, Sharan et al. 2012; Wong, Sceneay et al. 2012), lung 
(Ahmed, Schmidt et al. 2008), pancreatic (Schmidt, Park et al. 2007), prostate 
(Qi, Nakayama et al. 2010; Qi, Tripathi et al. 2013), liver (Malz, Aulmann et 
al. 2012) and melanoma (Qi, Nakayama et al. 2008). Additionally, Siah2 
protein levels are significantly increased in the ductal carcinoma in situ 
(DCIS) tumor tissue in high-grade breast cancer (Behling, Tang et al. 2011; 
Wong, Sceneay et al. 2012), lung cancer (Ahmed, Schmidt et al. 2008), and 
prostate cancer (Qi, Nakayama et al. 2010), compared with its expression in 






Table 1. Oncogenic role of Siah2 in various cancers and their respective 














Mouse model of 
breast cancer 
Inhibition of Siah2 with PHYL reduced tumor 
growth (Moller, House et al. 2009) 
Mouse model of 
spontaneous   
breast cancer 
Siah2-knockout mice show delayed breast 
tumor onset, reduced stromal infiltration, and 
altered tumor  angiogenesis (Wong, Sceneay 




High Siah expression predicts DCIS 
progression to invasive breast cancer 
(Behling, Tang et al. 2011) 
Human breast 
cancer tissue 
Siah2 upregulation in basal-like breast 
cancers (Chan, Moller et al. 2011) 
Human cell line 
 
Src/Siah2 mediates degradation of C/EBP, a 
tumor suppressor protein (Sarkar, Sharan et 
al. 2012). Inhibition of Siah2 in fibroblasts 
and in the non-transformed mammary 
epithelial MCF10A cells confers resistance to 
the transforming activity of Ras and Src 
oncogenes, respectively 
Human cell line Estrogen increases Siah2 levels in estrogen 
receptor ER positive breast cancer cells, 
resulting in degradation of the nuclear 
receptor corepressor 1 (N-CoR) and a 
reduction in N-CoR–mediated repressive 
effects on gene expression, thus promoting 









Mouse model of 
melanoma 
Inhibition of Siah2 activity reduces 
melanoma progression via HIF dependent and 
independent pathways (Qi, Nakayama et al. 
2008) 
Mouse model of 
melanoma 
Siah2 inhibition with vitamin K3 blocks 
melanoma progression by disrupting hypoxia 




















Reduced tumor progression and metastasis in 
Siah2-null prostate cancer mice (Siah2-
dependent regulation of Hif and FoxA2 
interaction). Increased Siah2 expression in 
human NE prostate tumor samples (Qi, 




The above studies support an oncogenic role of the Siah2 protein in 
promoting cancer and suggest that two main pathways are associated with it, 
for its activity: the hypoxic response pathway (prostate, melanoma, and breast 
cancer models) and the Ras signaling pathway (lung, pancreatic, and 
melanoma cancer models). The role of siah2 in these pathways are reviewed 
by Moller (House, Moller et al. 2009). 
 
1.1.8.1 Hypoxia signaling connected to Siah2 in cancer 
 Growth of solid tumors is associated with a poor oxygen supply 
(hypoxia) within the tumor mass, triggering a hypoxic response necessary to 
recruit new vasculature resulting in tumor cell survival (Seta, Spicer et al. 
2002).  HIF, the master regulator of hypoxia responses, has been implicated in 
cancer. HIF consists of a heterodimer between α-subunit (HIF-1α or HIF-2α) 
and β-subunit (HIF-1β). In a normoxic condition, the HIF-α level is regulated 
by the PHD (prolyl-hydroxylase) mediated hydroxylation of two proline 
residues that leads to VHL-dependent degradation (Maxwell, Wiesener et al. 




tissue and cell 
line  
Siah2 expression is upregulated in Castration-
Resistant Human Prostate Cancer [CRPC] 
tissues. Saih2 mediates the degradation of 
NCOR1-bound, transcriptionally-inactive AR 
(Androgen Recepor) there by promoting 
expression of AR target genes, a key player in 
CRPC. Knockdown of Siah2 or AR 
signiﬁcantly reduced proliferation of Rv1 and 
LNCaP cells. Inhibition of Siah2 promotes 
prostate cancer regression upon castration. 













mouse model of 
lung cancer 
Disrupting Siah2 function in lung cancer 
induced apoptosis and prevented tumor 














mouse model of  
pancreatic 
cancer 
Siah mediates Ras signaling in pancreatic 









 Human HCC 
tissue and cell. 
Nuclear accumulation of Siah2 enhances 
motility and proliferation of liver cancer cells  
(Malz, Aulmann et al. 2012). Inhibition of 
Siah2 expression also directly sensitizes 
human hepatocellular carcinoma (HCC) cells 
to treatment with cytostatic drugs 
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1999). However under a hypoxic condition HIF-1α triggers a response that 
includes the expression of genes like VEGF necessary to recruit new blood 
vessels thus playing an important role in promoting tumor cell survival. A 
cancer response to hypoxia not only sustains tumor growth and survival, but 
through angiogenesis it fosters invasion and metastasis (Brizel, Scully et al. 
1996). This pathway is well reviewed in (Semenza 2007). 
 Studies provide a link between Siah2 and HIF in tumor development 
and progression (Qi, Nakayama et al. 2008; Qi, Nakayama et al. 2010). Siah2 
is subjected to phosphorylation, which increases its ubiquitin targeted 
degradation activity under hypoxia conditions through mitogen-activated 
protein kinase (MAPK) p38 signaling cascade (Khurana, Nakayama et al. 
2006) . Essentially, Siah2 is induced under hypoxic conditions, that  control 
the stability of prolyl hydroxylases, PHD3 and PHD1 (Nakayama, Frew et al. 
2004), resulting in proteasomal degradation of hydroxylases and  impairment 
of HIF-1α (Qi, Nakayama et al. 2008), which is essential for HIF-1a’s 
association with and ubiquitination by pVHL (Ivan, Kondo et al. 2001).  
 Another study reports that Siah2 controls the levels and activity of 
HIF-1α, which cooperates transcriptionally with FoxA2 to promote NE tumor 
development or formation of NED of human prostate cancers. However, in 
this study the signaling pathway of how Siah2 regulates HIF-1α is not 
described (Qi, Nakayama et al. 2010).  
 Thus the studies in various mouse models show that Siah2 indirectly 
controls HIF-1α abundance, and is known to have a potential role in tumor 
development. Furthermore results showed that Siah2 seems to promote 
vasculogenesis, cell growth and metastasis (Fig. 4) (Qi, Nakayama et al. 
2008). 
 Siah2 knockout mice have a delayed and abrogated response to 
hypoxic conditions. At a cellular and tissue level, exposure of Siah2 mutants 
to hypoxia leads to significantly lower protein levels of HIF-1α, resulting in 
reduced hypoxia-induced gene expression (Nakayama, Frew et al. 2004). 
Consistent with this, a number of studies have shown that inhibition of Siah2 
activity reduces HIF-1α levels under hypoxic conditions that subsequently 
blocks the formation of tumors and reduced metastasis (Qi, Nakayama et al. 
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2008; Moller, House et al. 2009; Shah, Stebbins et al. 2009; Qi, Nakayama et 
al. 2010). 
 In addition, Siah2 has also been shown to regulate the stability of 
HIPK2 (Calzado, de la Vega et al. 2009), a transcriptional repressor of the 
HIF-1α gene (Nardinocchi, Puca et al. 2009). HIPK2 directly phosphorylates 
Siah2 resulting in a disruption of the HIPK2/Siah2 interaction, thus stabilizing 
HIPK2 and promoting apoptosis. 
 
   
 
 
Figure 4. Hypoxic signaling connected to Siah2. Under the hypoxia 
condition, hypoxia-activated p38 and Akt pathways positively regulate Siah2 
activity through phosphorylation and induction, respectively. Siah2 is 
phosphorylated by p38 on its serine and threonine residues, which will 
enhance its activity. Akt pathway increases the abundance of Siah2 by 
induction of its mRNA through signaling pathways yet to be clarified. Induced 
and activated Siah2 modulates the hypoxic signaling through PHD3 
degradation and HIF-1α stabilization on one hand. Although, it is not yet 
identified, other Siah2 substrates would also play roles on hypoxic signaling 
by both HIF-1α-dependent and -independent mechanism. Adapted from 
(Nakayama, Qi et al. 2009). 
  
 
1.1.8.2 RAS signaling connected to Siah2 in cancer 
 Siah2 enhances the MAPK-ERK signaling pathway, primarily through 
direct ubiquitination-dependent modulation of Sprouty2 (SPRY2), a Ras 
15 
inhibitory protein that negatively regulates the MAPK-ERK signaling 
(Nadeau, Toher et al. 2007; Shaw, Meissner et al. 2007). Inhibition of Siah2 
reduced Erk signaling, cell proliferation and increased apoptosis in various 
cancers (Schmidt, Park et al. 2007; Ahmed, Schmidt et al. 2008; Qi, 
Nakayama et al. 2008). In addition, attenuation of Sprouty2 expression 
effectively restores phospho-ERK levels in Siah2-inhibited melanoma cells 
and partially rescues tumor formation in vivo (Nadeau, Toher et al. 2007). 
 Inhibition of Siah2 activity by a dominant negative Siah2 RING 
mutant in SW1 melanoma cells resulted in reduced tumor growth and 
metastases by robustly upregulating the  levels of SPRY2 a specific inhibitor 
of Ras/ERK signaling. In contrast, the RING mutant inhibition of Siah1 has 
only little effect on levels of PHD3 and HIF-1α in SW1 cells (Shaw, Meissner 
et al. 2007). However inhibition of Siah2 substrate binding through PHYL (a 
peptide inhibitor for Siah2) reduced only metastatic spread and not tumor 
growth in melanoma cells growth via the hypoxic response pathway (Qi, 
Nakayama et al. 2008; Moller, House et al. 2009). 
 These studies suggest that Siah2 may act through both pathways 
simultaneously or through different pathways at different stages of tumor 
progression. Consistent with the important role of Siah2 in HIF and ERK 
signaling, vitamin K3, a Siah2 inhibitor, reduces HIF and phospho-ERK levels 
in a human melanoma cell line and inhibits tumor formation in the mouse 
xenograft model (Shah, Stebbins et al. 2009). Taken together, these 
observations provide a foundation for the development of Siah2-targeted 
therapeutic agents for cancer therapy.  
 
1.1.9 E3 ubiquitin ligases as a cancer target 
 E3 ubiquitin ligases regulate a variety of biological processes, 
including cell growth and apoptosis, through the timely ubiquitination and 
degradation of many cell cycle- and apoptosis-regulatory proteins. Abnormal 
regulation of E3 ligases has been convincingly shown to contribute to cancer 
development (Nakayama and Nakayama 2006). Thus, targeting E3 ubiquitin 
ligases for cancer therapy has gained increasing attention, which is further 
stimulated by the recent approval of a general proteasomal inhibitor, 
bortezomib (Velcade, Millennium, MA), for the treatment of relapsed and 
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refractory multiple myeloma (Richardson, Mitsiades et al. 2006), as well as for 
the discovery of a new class of proteasome inhibitors (Chauhan, Catley et al. 
2005).  Targeting a particular E3 ubiquitin ligase rather than the total 
proteasome system is expected to increase specificity and limit toxicity. This 
became even more blossomed after the approval of SMAC mimetics, a small 
inhibitor for E3 IAP family (Feltham, Bettjeman et al. 2011). 
1.1.10 Protein-Protein Interactions as drug targets 
 Protein-Protein interactions (PPIs) are essential for many biological 
functions. Numerous investigations in genomics, proteomics and 
bioinformatics have provided convincing experimental evidence that PPIs 
participate in networks of interactions that may also involve other biological 
macromolecules (Schwikowski, Uetz et al. 2000; Schächter 2002). PPIs are 
increasingly attracting attention as a new frontier in drug development, 
particularly where they are involved in the regulation of cellular function and 
disease states. The advantage of targeting PPIs is mainly the biological 
specificity of inhibition (Valkov, Sharpe et al. 2012). It might, therefore, be 
possible to limit the adverse effects of a drug by selectively targeting one of 





1.2 Drug Development 
1.2.1 Introduction to drug discovery 
 The search for new, effective and safe drugs has become increasingly 
sophisticated. Two pronounced characteriztics marked the modern age of the 
pharmaceutical industry: “competitiveness” and “high cost”. Driven by the 
high exclusive marketing profit, competition between pharmaceutical 
companies is much more intensive than before (Drews and Ryser 1997).  
 “Innovate or die” is the first rule of international industrial 
competition. The cost of discovering a new drug is becoming very high. The 
initial statistics of drug discovery usually shows that it would take 12-15 years 
and more than $1 billion to discover a new drug and this cost has been 
growing at a rate of 20% per year (Heilman 1995; Yevich 1996). To alleviate 
this problem, efforts have been directed to reduce the cost and the time span 
needed for the discovery of a new drug. In consideration of the current patent 
protection period of 20 years for new drugs, any advance in marketing a drug 
more quickly is desirable. In addition to its great contribution to the 
improvement of our life qualities, earlier marketing is also enormously 
profitable. 
 
1.2.2 Stages in drug development and the role of in silico approaches 
 The stages of drug development are simplified as follows, 
1. Pre-Clinical trials (also known as Phase 0). This phase mainly 
consists 
 Discovery phase: identification of target  
  Lead identification and optimization 
 Toxicology 
2. Clinical development: Phase1, 2 & 3 
3. Marketing  
 The hierarchical process of traditional drug discovery after the target is 
identified is outlined in Fig. 8. As the preclinical stage normally takes about 6 
years, and if it were to be shortened to 2 or 3 years, not only a big amount of 
research and development funding could be saved, but also the more important 
and exclusive clinical and marketing periods would be benefited. More and 
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more computer approaches are now being developed to reduce the cost and 
cycle time for discovering a new drug. In silico approaches in drug discovery 








 The first step is to identify suitable biological targets, such as hormone, 
receptor, enzyme, peptide and nucleic acid based on a thorough understanding 
of regulatory networks and metabolic pathways. The second step is to design a 
highly specific drug based on the known three-dimensional (3D) structure of 
that target. 
 X-ray crystallography is the most powerful technique for determining 
the three-dimensional structure of a protein but this can be a time-consuming 
process, and it will succeed only if it is possible to find suitable conditions for 
growing crystals. This can therefore easily become a bottleneck in drug 
designing projects. Also, some proteins have highly flexible domains making 
it difficult to crystallize them. Since the number of protein folds used by  
Nature is limited, homologous proteins can be expected to have a similar fold 
(Govindarajan, Recabarren et al. 1999). Hence homology based modeling, 
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which is discussed in section 1.14.1 is a practical and reasonable alternative to 
crystallography. 
 
Lead identification and optimization 
 The step of lead discovery is considered a bottle-neck of the drug 
discovery process (Kenny, Bushfield et al. 1998; Langer and Hoffmann 2001). 
In the past, leads were mainly discovered by random screening of a large 
chemical library. The sources of chemicals can be diverse such as active 
ingredients of natural products, derivatives of existing drugs, or even 
randomly synthesized chemicals. Most large pharmaceutical companies have 
their own libraries, which contain the chemicals accumulated from years of 
efforts. It was reported that only one potential lead can be identified from 
random screening of  5-10 thousand chemicals (Yevich 1996). Therefore, the 
efficiency of mere screening is very low. The increasingly better 
understanding of a drug-target interaction mechanism and rapid advances in 
biochemistry and organic chemistry lead to the advent of computer aided drug 
design (CADD), which aims to help the rapid and efficient discovery of drug 
leads (Marshall 1987; Vedani 1991; Ooms 2000; Veselovsky and Ivanov 
2003; Bienstock 2012; Chen 2013). The role of CADD in lead identification 
and optimization has been discussed in Section 1.14 
 
Toxicology 
  In pre-clinical treatment before administering to human, in vitro and in 
vivo tests of a lead molecule are conducted. Acute and short term toxicity of 
lead molecules are evaluated on animals. The physiological and biological 
effects of lead molecules are observed and a molecule is absorbed, distributed, 
metabolized and excreted in animals need to be addressed. The lethal dose 
limits of a lead molecule is determined in this phase. Only one out of 
approximately 5000-10000 molecules facing pre-clinical tests is usually 
approved for marketing (Klees and Joines 1997). 
 Clinical trials involving new drugs are commonly classified into four 
phases. Each phase of the drug approval process is treated as a separate 
clinical trial.  
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Phase 1: Screening for safety. (human pharmacology) 
 Phase I studies are used to evaluate pharmacokinetic parameters and 
tolerance, generally in healthy volunteers, normally about 20-80 individuals. It 
is the first stage to test a drug on human subjects. The test usually starts with 
very small doses and subsequently increased. Escalating doses of a drug are 
administered to determine the maximum tolerance dose (MTD), which can 
induce the first symptom of toxicity.  
 
Phase 2: Establishing a testing protocol. (therapeutic exploratory) 
  After the Phase I trials, when the initial safety levels of a drug have 
been confirmed, Phase II clinical studies are conducted on about 100 to 300 
patients to assess the efficacy of a lead molecule and to determine how well 
the drug works. Additional safety, clinical and pharmacological studies are 
also included in this study. During this phase, effective dose, method of 
delivery, safety and dose intervals of a lead molecule are established. 
 
Phase 3: Final testing. (therapeutic confirmatory) 
  In Phase 3 trials, treatment is given to a large group of people (1,000-
3,000) to confirm the effectiveness of a drug, monitor side effects, compare it 
to commonly used treatments, and collect information that will allow a drug to 
be used safely. 
 The drug-development process will normally proceed through all four 
phases over many years. If the drug successfully passes through Phases 1, 2, 
and 3, it will usually be approved by the national regulatory authority of a 
country for use in the general population. 
 
Phase 4: Post approval studies. I 
  Phase 4 trials, post-marketing studies delineate additional information, 
including the risk of treatment, benefits, and optimal use.  
 
1.2.3 Computer-aided drug design (CADD) 
Computer-aided drug design is typically carried out by 
computationally docking sets of small molecular compounds and peptides into 
a rigid model of the active site of a protein. In the past, docking methods were 
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primarily used to identify a small set (10–100), of molecules, which would be 
active against a single target. More recently, docking methods have been used 
to prioritize combinatorial libraries and create screening libraries focused on 
specific gene families/macromolecular targets. Following are the approaches 
involved in CADD. 
 
1.2.3.1 Homology modeling 
 Homology modeling aims to build three-dimensional protein structure 
models using experimentally determined structures of related family members 
as templates based on the observation that the structures are more conserved 
than the corresponding sequences (Lesk and Chothia 1980; Chothia and Lesk 
1986). The active site can have very similar geometries, even for distantly 
related proteins (Zvelebil, Barton et al. 1987; Raha, Wollacott et al. 2000). The 
methodology involves four steps: template selection, sequence alignment, 
model building and model validation (Brenner, Chothia et al. 1998; Al-
Lazikani, Jung et al. 2001). 
 
Template identification and selection 
 Template selection starts with identifying one (or more) experimentally 
determined structures (the template), which is likely to have structure 
homology with the sequence of interest (the target). Heuristic search methods 
such as BLAST (Altschul, Gish et al. 1990) and FASTA (Pearson and Lipman 
1988),  are often used for this as they are fast and accurate. In difficult cases 
more sensitive fold recognition methods, which utilize techniques such as 
hidden Markov methods, neural networks, iterated searches (e.g. PSI-BLAST 
(Pearl, Martin et al. 2001)), and evolutionary information that offer high 
relaiablility for the model and can be used to scan a structural database for 
suitable templates (Edwards and Cottage 2003). 
 
Target and template sequence alignment 
 Once the best template for modeling is identified, an optimal alignment 
of the target and template must be made. The alignment created by a search 
method or a fold recognition method may be sub-optimal with respect to 
modeling. Different score matrices are needed in order to get an optimal 
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alignment for homology modeling as compared to fold recognition, possibly 
because fold recognition needs to focus on conserved regions whereas 
homology modeling needs to take all regions into account. The Smith-
Waterman algorithm uses dynamic programming to find an optimal alignment 
between two sequences, given a scoring matrix and a gap model (Smith and 
Waterman 1981).  
 If multiple templates were found with significant sequence similarity, 
then the use of alignments based on multiple sequences is implied, as it 
highlights evolutionary relationships, and increase the alignment accuracy 
(Jaroszewski, Rychlewski et al. 2000). Several tools like ClustalX (Thompson, 
Gibson et al. 1997), and T-Coffee (Notredame, Higgins et al. 2000) serve this 
purpose. Other interesting methods include machine learning fast Fourier 
transform, improved score matrices and new scoring functions have also been 
developed to give a quantitative measure of alignment accuracy (Cristobal, 
Zemla et al. 2001; Karwath and King 2002). If sequence similarity is low, then 
structurally aligned templates are a good starting point to improve the 
alignment quality (Yang 2002). DALI (Holm and Sander 1993) is an example 
of the multiple structural and templates alignment templates.  
 
Model building  
 Model building consists of three main steps which involves main-chain 
building, loop modeling, basically de novo model building and side-chain 
modeling, an optimization step. Building the core is based on the approaches 
like rigid body superimposition that constructs the model from a few core 
sections defined by the average of Cα atoms in conserved regions. Distance 
geometry uses spatial restraints obtained from alignment. Segment matching 
uses a database of short segments of a protein structure, with a combination of 
energy and geometry rules (Deane, Kaas et al. 2001). Several programs are 
available for homology modeling.  SwissModel (Guex and Peitsch 1997)  a 
popular implementation of the rigid body approach is a commonly used online 
tool. The backbone is rebuilt based on the positions of Cα atoms, using a 
library of backbone elements derived from high quality Xray structures.  
 Homology modeling in MODELLER (Sali and Blundell 1993) is very 
reliable and is performed based on satisfying  spatial restraints. Distance and 
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dihedral angle restraints on the target structure are also generated, based on the 
alignment to the template structure. Corresponding distances and angles 
between aligned residues in the template and target structures are assumed to 
be similar. Restraints on bond lengths, bond angles, dihedral angles and non-
bonded atom-atom contacts are also derived from statistical analysis of the 
relationships between Cα atoms, solvent accessibilities and side-chain torsion 
angles in known protein structures. The restraints are expressed as probability 
density functions (pdfs). These pdfs are combined to give a molecular 
function, which is optimized using a combination of energy minimization with 
molecular dynamics and simulated annealing. 
 
1.2.3.2 Molecular dynamics simulation 
 Molecular dynamics (MD) simulation is a computer simulation of the 
physical movements of atoms and molecules which are allowed to interact for 
a period of time.  Computer simulations are also an alternative to complex 
experiments to predict the thermodynamic and kinetic roles of amino acids in 
proteins (Dokholyan, Buldyrev et al. 1998; Munoz and Eaton 1999). 
Molecular dynamics investigates the motion of discrete particles described by 
a potential energy function under external forces and quantifies them (Kandt, 
Ash et al. 2007). With the knowledge of these forces it is possible to calculate 
the dynamic behavior of the system using classical equations of motion. This 
potential energy function that consists of a set of equations that empirically 
describe bonded and non-bonded interactions between atoms is referred to as 
“force field” (Ponder and Case 2003). The bonded interactions between atoms 
are via covalent bonds, which typically includes bonds, bond angles, and 
dihedrals. Non-bonded interactions are electrostatic interactions between the 
partial charges on each atom and a Lennard-Jones potential to model 
dispersive van der Waals interactions. Each molecule in the simulation is 
described by its ‘topology’, the combination of the set of all atoms with their 
non-bonded and bonded interaction parameters and the connectivity of those 
atoms in the molecule's in silico MD simulations and provides a means to 
facilitate the interpretation of experimental data.  
 On the other hand, the complexity and vast dimensionality of the 
protein conformational space makes the folding time too long to be reachable 
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by computational studies at the atomic detail (Taketomi, Ueda et al. 1975; 
Shakhnovich 1997). Simplified models became popular due to their ability to 
reach reasonable time scales and to reproduce the basic thermodynamic and 
kinetic properties of proteins (Privalov 1989). They are (i) unique native state 
(NS), i.e. there should exist a single conformation with the lowest potential 
energy (ii) cooperative folding transition (iii) thermodynamical stability of the 
NS (iv) kinetic accessibility, i.e. the NS should be reachable in a biologically 
reasonable time. 
 Simulation of complex systems of hundreds and millions of atoms is 
achieved by GROMACS (see www.GROMACS.org), one of the fastest and 
most popular molecular dynamics software packages. GROMACS was 
designed primarily for simulations of nucleic acids, proteins, and lipids based 
on non-bonding interactions. The software is not capable of simulations where 
bonds are broken and reformed, such as chemical/enzymatic reactions. But for 
situations where non-bonding interactions are expected to predominate, 
GROMACS can provide information about the behavior of solute and solvent 
molecules, and potentially support and explain experimental data. 
 
1.2.3.3 Structure based drug design (SBDD) 
A drug is most commonly a small organic molecule that activates or 
inhibits the function of a biomolecule such as a protein which in turn results in 
a therapeutic benefit to a patient. In most cases, drug designing involves the 
development of small molecules that are complementary in shape and charge 
to a biomolecular target with which they interact. (Cohen 1996). Structure-
based drug design relies on the knowledge of the three dimensional structure 
of a biological target obtained through methods such as X-ray crystallography 
or nuclear magnetic resonance (NMR) spectroscopy (Leach and Jhoti. 2007). 
If an experimental structure of a target is not available, it may be possible to 
create a homology model of the target, based on the experimental structure of 
a related protein as discussed earlier in Section 1.14. In such cases, SBDD 
frequently relies on computational techniques and involves iterative steps of 
identifying new therapeutics based on a particular biological target (Madsen, 
Krogsgaard-Larsen. et al. 2002). Using the structure of a biological target, 
candidate drugs that are predicted to bind with high affinity and selectivity 
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may be designed using interactive graphics and the intuition of medicinal 
chemistry. Alternatively various automated computational procedures may be 
used to suggest new drug candidates. The complete iterative process of this is 




Figure 6. Integration of structural and informatics methods. The diagram 
illustrates how different computational approaches complement each other in 
the context of structure-based drug design (Tang and Marshall 2011). 
 
 
SBDD can potentially reduce the numbers of compounds that need to 
be evaluated, and lead to new directions for synthetic optimization (Scapin 
2006). Current methods for structure-based drug designing can be divided 
roughly into two categories. The first category is about “finding” ligands for a 
given target which is usually referred as database searching. In this case, a 
large number of potential ligand molecules are screened to find those fitting 
the binding pocket of the target. This method is usually referred as ligand-
based drug design. The key advantage of database searching is that it saves 
synthetic effort to obtain new lead compounds. Another category of structure-
based drug design methods is about “building” ligands, which is usually 
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referred as receptor-based drug design. In this case, ligand molecules are built 
up within the constraints of the binding pocket by assembling small pieces in a 
stepwise manner. These pieces can be either individual atoms or molecular 
fragments. The key advantage of such a method is that novel structures, not 
contained in any database, can be suggested (R., Y. et al. 2000; Jorgensen 
2004; Schneider and Fechner 2005). 
 
1.2.3.4 Active site identification 
Active site identification is the first step in this program. It analyses a 
protein to assign a suitable drug binding pocket, derives key interaction sites 
within the binding pocket, and then prepares necessary data for ligand-
fragment link. The basic inputs for this step are the 3D-structure of the protein 
and a pre-docked ligand, as well as their atomic properties. Both ligand and 
protein atoms need to be classified and their atomic properties should be 
defined, basically, into four types: hydrophobic atoms (all carbons); H-bond 
donor (oxygen and nitrogen atoms bonded to hydrogen atoms); H-bond 
acceptor (oxygen and sp2 or sp hybridized nitrogen atoms with lone electron 
pairs); polar atom (oxygen and nitrogen atoms that are neither H-bond donor 
nor H-bond acceptor, sulphur, phosphorus, halogen, metal, and carbon atoms 
bonded to hetero-atoms). 
The space inside the ligand binding region would be studied with 
virtual probe atoms of the above four types so that the chemical environment 
of all spots in the ligand binding region can be known. This will suggest what 
kind of chemical fragments can be put into their corresponding spots in the 
ligand binding region of the target.  
A typical in silico drug design cycle consists of docking, scoring and 
ranking initial hits on the basis of their steric and electrostatic interactions with 
the target site, which is commonly referred to as virtual screening. 
 
1.2.3.5 Virtual screening 
High-throughput screening is the most common experimental method 
used to identify lead compounds. Because of the cost, time, and resources 
required for performing high-throughput screening for compound libraries, the 
use of alternative strategies is necessary for facilitating lead discovery. Virtual 
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screening has been successful in prioritizing large chemical libraries to 
identify experimentally active compounds, serving as a practical and effective 
alternative to high-throughput screening. 
Virtual screening is a computational method for identifying lead 
compounds from large and chemically diverse compound libraries from public 
or specifically compiled databases of hundreds of thousands of organic or 
synthetic compounds (Oprea and Matter 2004; Shoichet 2004)  
It is always advantageous to begin the screening with established drug 
compounds. This will enable a developer to rapidly prototype a candidate 
ligand whose chemistry is well known and within the intellectual property of 
the developer. The initial successful hits are called lead compounds. The 
interaction of a lead compound with its target can be verified by X-ray 
crystallography, if possible. From this point onward, a cycle of iterative 
chemical refinement and testing continues until a drug is developed that 
undergoes clinical trials.  
 As a consequence of lack of knowledge about function-determining 
features of desired ligand molecules in the early stages of the discovery 
process, virtual screening had become a complementary strategy to high 
throughput screening (HTS) as follows.  
1.  By suggesting new chemical entities that are designed by taking into 
consideration of several aspects of lead and drug-likeness and synthetic 
accessibility; by making full use of pre-existing knowledge, such as reference 
ligands or receptor models.  
2. By facilitating the designing of, activity enriched screening sets with 
increased hit rates. This computational method is valuable for discovering lead 
compounds in a faster, more cost-efficient, and less resources-intensive 
manner compared to experimental methods such as high-throughput screening. 
The virtual screening could be separated into two steps: docking and scoring 
(Tang and Marshall 2011) .  
 Methodologies used in virtual screening, such as molecular docking 
and scoring, have advanced to a point where they can rapidly and accurately 





The docking process involves the prediction of ligand conformation 
and orientation (called posing) within the binding site of a target (Fig. 7).  In 
general, there are two aims of docking studies: accurate structural modeling 
and correct prediction of activity. However, the identification of the molecular 
features that are responsible for specific biological recognition, or the 
prediction of compound modifications that improve potency, are complex 
issues that are often difficult to understand and even more so to simulate on a 
computer. 
In view of these challenges, docking is generally devised as a multi-
step process in which each step introduces one or more additional degree of 
complexity (Brooijmans and Kuntz 2003). The process begins with the 
application of docking algorithms that place small molecules in the active site. 
The outcome of this process determines whether a given conformation and 
orientation of a ligant fits the active site. This in itself is challenging, as even 
relatively a simple organic molecule can contain many conformational degrees 
of freedom.  
Sampling these degrees of freedom must be performed with sufficient 
accuracy to identify the conformation that best matches a receptor structure, 
and must be fast enough to permit the evaluation of thousands of compounds 









Figure 7. A docked pose of a ligand and protein receptor in its active site. 
(a) The compound is displayed in ball and sticks and the macromolecule is 
displayed as surface representation by use of PyMOL. (b) A diagram 
illustrating the docking of a small molecule ligand (brown) to a protein 
receptor (green) to produce a complex. 
 
 Algorithms are complemented by scoring functions (both posing and 
ranking involve scoring). The pose score is often a rough measure of the fit of 
a ligand into the active site. The rank score is generally more complex and 
attempt to estimate binding energies. The scores are designed to predict the 
biological activity through the evaluation of interactions between compounds 
and potential targets. Early scoring functions evaluated compound fits on the 
basis of calculations of approximate shape and electrostatic complementarities. 
Relatively simple scoring functions continue to be heavily used, at least during 
the early stages of docking simulations. Pre-selected conformers are often 
further evaluated using more complex scoring schemes with a more detailed 
treatment of electrostatic and Van der Waals interactions, and inclusion of at 
least some solvation or entropic effects (Gohlke and Klebe 2002). It should 
also be noted that ligand binding events are driven by a combination of 
enthalpic and entropic effects, and that either entropy or enthalpy can 
dominate specific interactions. This often presents a conceptual problem for 
contemporary scoring functions (discussed below), because most of them are 
much more focused on capturing energetic than entropic effects. 
 In addition to the problems associated with scoring of compound 
conformations, other complications exist that make it challenging to accurately 
b a 
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predict binding conformations and compound activity. These include, among 
others, limited resolution of crystallographic targets, inherent flexibility, 
induced fit or other conformational changes that occur on binding, and the 
participation of water molecules in protein–ligand interactions.  
 
1.2.3.7 Scoring methods 
 Structure-based drug designing attempts to use the structure of proteins 
as a basis for designing new ligands by applying accepted principles of 
molecular recognition. The basic assumption underlying structure-based drug 
designing is that a good ligand molecule should bind tightly to its target. Thus, 
one of the most important principles for designing or obtaining potential new 
ligands is to predict the binding affinity of a ligand to its target and use it as a 
criterion for selection. It gives the best possible conformation of the ligand to 












A method was developed by Bohm (Bohm 1994) to develop a general-purpose 
empirical scoring function in order to describe binding energy.  
The following equation (Eq.1) was derived: 
            Gbind       Kd 
              Kd 
                    
         
 
 Gbind =  Gdesolvation +  Gmotion +  Gconfiguration +  Ginteraction       Eq. 1 
 where: desolvation is the enthalpic penalty for removing the ligand 
from solvent; motion is the entropic penalty for reducing the degrees of 
freedom when a ligand binds to its receptor; configuration is the 
conformational strain energy required to put the ligand in its "active" 
conformation; interaction is the enthalpic gain for resolvating the ligand with 
its receptor. 
 The basic idea is that the overall binding free energy can be distributed 
into the independent components that are known to be important for the 
binding process. Each component reflects a certain kind of free energy 
alteration during the binding process between a ligand and its target. The 
master equation is the linear combination of these components. According to 
the Gibbs free energy equation, a relationship between the dissociation 
equilibrium constant, Kd, and the components of free energy can be built. 
 Various computational methods are used to estimate each of the 
components of the equation. For example, the change in polar surface area 
upon ligand binding can be used to estimate the desolvation energy. The 
number of rotatable bonds, frozen upon ligand binding, is proportional to the 
motion term. The configuration or strain energy can be estimated using 
molecular mechanics calculations. Finally the interaction energy can be 
estimated using methods such as the change in non-polar surface, statistically 
derived potentials of mean force and the number of hydrogen bonds formed. In 
practice, the components of the equation are fit to experimental data using 
multiple linear regression. This can be achieved with a diverse training set, 
including many types of ligands and targets to produce a less accurate but a 
more general global model or a more restricted set of ligands and targets to 
produce a more accurate but less general local  model (Gohlke, Hendlich et al. 
2000; Clark, Strizhev et al. 2002; Wang, Lai et al. 2002).  
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 Drug discovery pipelines in pharmaceutical companies are fuelled by 
HTS as one of the major sources of new hit-to-lead candidates. As 
experimental methods, such as X-ray crystallography and NMR, develop, the 
amount of information concerning 3D structures of biomolecular targets has 
increased dramatically. In parallel, the information about structural dynamics 
and electronic properties of ligands has also increased. This has encouraged 
rapid development of the structure-based drug designing.  
 
1.2.3.8 Adsorption, distribution, metabolism and excretion (ADME) 
While virtual screening was expected to generate new drugs easily, just 
by virtue of the sheer size of available libraries, in fact, things were not that 
straight forward (Lahana 1999). In the early days, many large sets of 
biologically inactive molecules were tested, most often as ill-defined mixtures. 
Library composition has subsequently been significantly influenced by Chris 
Lipinski, who formulated simple rules for predicting which compounds would 
support useful bioavailability (Lipinski, Lombardo et al. 2001). The 
bioavailability of drug molecules could be analyzed by its physicochemical 
properties using Lipinski’s rule of five.  
 According to Lipinksi's 'rule of five' (Lipinski, Lombardo et al. 2012), 
drug candidates should have a molecular mass below 500 Daltons, a 
lipophilicity below Log P = 5, and contain no more than 5 hydrogen bond 
donors and no more than 10 oxygen and nitrogen atoms. Furthermore, poor 
passive absorption is to be expected if two or more of these conditions are 
violated. As an alternative to the Lipinski rules, polar surface area (Ertl, Rohde 
et al. 2000) or VolSurf parameters (Cruciani, Pastor et al. 2000) can be used to 
predict oral absorption (Jorgensen 2004; Shoichet 2004; Scapin 2006; Leach 
and Jhoti. 2007) and blood–brain barrier penetration (Kelder, Grootenhuis et 
al. 1999; Cruciani, Pastor et al. 2000). The flexibility of molecules has been 
recognized as another factor influencing bioavailability (Veber, Johnson et al. 
2002). 
 Violation of the Lipinski rules was indeed the main reason for failure 
of early combinatorial libraries, and the application of the rules significantly 
aided improvements. In this context, two investigations are most often cited 
(Bohm 1994), which correlated about 40% of failures in clinical development 
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with inappropriate pharmacokinetics, that is, a lack of sufficient oral efficacy. 
Correspondingly, absorption, distribution, metabolism and excretion (ADME) 
parameters are now considered to be key factors in drug development. The 




 Figure 9. Schematic flow of virtual screening process. 
  
1.2.4 Successes and limitations of SBDD 
 Successes 
  SBDD has proven to be successful in the design of the following drugs 
which are already in clinical trials, of medically relevant proteins in complex 
with compounds developed during the drug discovery process. 
1. Dorzolamide (Ki = 0.37nM )(Glaucoma treatment) (Baldwin, 
Ponticello et al. 1989) 
2. Saquinavir, Indinavir, Ritonavir, Nelfinavir (HIV therapy) (Wlodawer 
and Vondrasek 1998; Edwards 2001) 
Agouron Pharmaceuticals and Vertex Pharmaceuticals, were both 
successful in designing the HIV protease inhibitors nelfinavir 3 (Ki = 
2.0nM) and amprenavir 4 (Ki = 0.6nM) 
3. Zamnavir: Neuroaminidase inhibitors (anti-influenza) (Fig. 10) (von 
Itzstein, Wu et al. 1993) 
100000 
• Available from public database 
1000 
• Screened and narrowed down to ‘n’ number of 
molecules based on pharmacokinetics properties 
(Lipinskis rule of five) using computational techniques 
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• Compounds  that  have better binding energy than 
known 
5 
• Analysed based on their specificity towards binding 
site residues 
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4. COX-2 inhibitors (anti-inflammatory) 




Figure 10. Docking pose of zanamivir (Relenza) bound to influenza 
neuraminidase. An example for structure based drug design showing ligand 
in virtual space docked with the crystal structure of the target protein. 
Residues involved in ligand binding are highlighted in three letter codes 
(Blundell, Jhoti et al. 2002).  
 
The design of estrogen receptor subtype-selective (ERα and ERβ) ligands is an 
exciting success story of homology modeling and structure-based design 
(Hillisch, Pineda et al. 2004). 
 These compounds go through numerous iterations as they progress 
towards clinical trials. In an industrial environment, where multiple projects 
are being worked simultaneously, with each of them likely having multiple 
compound series, the number of required total complex structures can be very 
high (hundreds per year). Also, the success ratio of crystals with the ligand to 
harvested crystals will be very small. The efficiency of the process can be 
improved only by using bioinformatics tools for sample tracking and 







Although docking is a relatively well-developed technique, it still 
suffers from some limitations. One limitation is that docking studies are 
typically carried out using a rigid target model. Although a few docking 
methods allow a certain degree of side-chain flexibility, these programs are 
currently unable to model loop movements or induced-fit effects, which are 
found in many systems (Ajay and Murcko 1995; Charifson, Corkery et al. 
1999; Muegge and Rarey 2001). Combinatorial chemistry and structure based 
validation assist the refinement process significantly. This is a very powerful 
technique that chemists employ to aid in the refinement of a lead compound. It 
is a synthetic tool that enables chemists to rapidly generate thousands of lead 
compound derivatives for testing. A scaffold is employed that contains a 
portion of the ligand that remains constant. Subsite groups are potential sites 
for derivatization. These subsites are then reacted with combinatorial libraries 
to generate a multitude of derivative structures, each with different substituent 
groups. If a scaffold contains three derivatization sites and the library contains 
ten groups per site, theoretically 1000 different combinations are possible. By 
carefully selecting libraries, based upon the study of the active site, we can 
target the derivatization process towards optimizing ligand receptor 
interaction. 
 
1.3 Protein crystallization and data collection 
Protein crystals can be interpreted as an infinite array in which a 
minimum volume (known as a unit-cell) is repeated in three-dimensional 
space and within a unit-cell molecules are arranged following well-defined 
symmetry rules. Growth of a single and well defined diffracting crystal forms 
the basic and essential prerequisite for X-ray crystallographic protein structure 
determination (Blow 2002). Producing high quality crystals has always been 
the bottleneck in structure determination and it is still not understood why 
some proteins crystallize with ease while others stubbornly refuse to produce 
suitable crystals (Chayen 2004). Crystallization requires that a protein is first 
be purified to homogeneity and then concentrated to a supersaturated state. 
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 Crystal growth has three steps: nucleation, growth and cessation of 
growth. However, identifying a successful crystallization condition for a new 
protein is like looking for a needle in a haystack (McPherson 2009). Also, 
truncation of a protein at the flexible N or C terminus may lead to proper 
crystallization and diffraction. In addition, tagging a partially soluble or 
partially homogeneous protein with maltose binding protein (MBP) (Gruswitz, 
Frishman et al. 2005) or other tags (Cherezov, Rosenbaum et al. 2007) at the N 
or C terminus has given a positive effect in crystal formation (nucleation site 
for crystal formation) as well as in enhancing solubility. Different techniques 
are employed for setting up crystallization trials, which include sitting drop 
vapor diffusion, hanging drop vapor diffusion, sandwich drop, batch, micro 
batch under oil, micro dialysis and free interface diffusion. While vapor 
diffusion has been very popular and successful for the past 40 years, 
microbatch, which is the simplest method, is a relatively new technique. 
 Sitting and hanging drop methods are easy to manipulate, require a 
small amount of sample, and allow large amount of flexibility during 
screening and optimization. Once a lead is obtained as to which conditions 
may be suitable for crystal growth, the conditions can generally be fine-tuned 
by making variations to the parameters including precipitant, pH, salt, 
temperature, etc. Cryo-preservation of good crystals is also a defining factor in 
protein crystallography. This is helpful in protecting a protein crystal from the 
naturally damaging effects of X-rays during data collection. Usually, glycerol, 
sucrose, propanediol, glycol, etc. are used for cryo-preservation. No additional 
cryo protection agent is needed if a crystal is already grown in some natural 
cryo buffers or glutaraldehyde. 
 
Objectives 
1. To identify specific drug targets towards the substrate binding domain 
(SBD) of Siah2 using in silica high throughput virtual screening (HTVS)  
2. To validate the potential drug targets using in vitro and in vivo binding 
assays, and  
3. To identify the critical amino acid residues involved in the 
binding/interaction between Siah2 and the target molecules.  
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CHAPTER 2. MATERIALS AND METHODS 
 
2.1 Homology modeling 
 Homology modeling of the SBD of Siah2 was built using Modeller 9v7 
software (Sali and Blundell 1993).  The amino acid sequence of human Siah2 
was retrieved from GenBank (accession number: NM_005067) in NCBI 
(McGinnis and Madden 2004). It consists of 324 amino acids of which, 
residues from 130-322 belongs to SBD. The SBD was then subjected to PSI-
BLAST search (Altschul, Madden et al. 1997) in order to identify the 
homologous proteins from the Protein Data bank (PDB) (Berman, Henrick et 
al. 2003). An appropriate template for SBD was identified based on the e-
value and sequence identity. The template and the target sequences was then 
aligned using ClustalW (Thompson, Gibson et al. 2002). Subsequently, 
homology modeling for SBD of Siah2 against the chosen template was carried 
out using Modeller 9v7. The outcome of the modeled structures were ranked 
on the basis of an internal scoring function and those with the least internal 
scores were identified and utilized for model validation. 
 
2.2 Validation of the modeled structure 
 In order to assess the reliability of the modeled structure of SBD of 
Siah2, we calculated the root mean square deviation (RMSD) by 
superimposing with template structure using 3-dimensional structural 
superposition (3D-SS) tool (Sumathi, Ananthalakshmi et al. 2006). The 
backbone conformation of the modeled structure was calculated by analyzing 
the phi (Φ) and psi (ψ) torsion angles using PROCHECK (Laskowski, 
MacArthur et al. 1993) determined by the Ramachandran plot statistics. 
Finally, the quality of consistency between the template and the modeled 
Siah2 were evaluated using ProSA (Wiederstein and Sippl 2007), in which the 
energy criteria for the modeled structure  was compared with the potential 
mean force obtained from a large set of known protein structures. 
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2.3 Protein simulation 
 The stability of the modeled Siah2 was checked by molecular 
dynamics (MD) simulation using Gromacs software (Hess, Kutzner et al. 
2008).  The modeled SBD was energy minimized using optimized potentials 
for liquid simulations all-atom (OPLS) force field (McDonald and Jorgensen 
1998). This preliminary energy minimization was performed to discard the 
high energy intramolecular interactions. The overall geometry and atomic 
charges were optimized to avoid steric clashes. The modeled SBD was 
solvated in a rectangular box of about 16,614 water molecules using TIP3P 
model system in order to mimic the physiological behavior of the 
biomolecules (Jorgensen, Chandrasekhar et al. 1983). 
The energy of the modeled Siah2 was then minimized without 
restraints for 2000 steps using the above mentioned algorithms. The system 
was then gradually heated from 10 to 300 Kelvin over 5 nano seconds (ns) 
using the NVT ensemble. Finally MD simulation was carried out to examine 
the quality of the model structures by checking their stability and by 
performing a 5 ns simulation and the lowest energy structure during simulation 
was calculated. Similar protocol was followed for the template also in order to 




SBD of Siah2 was modeled computationally and its active sites were 
predicted using SiteMap (version 2.3, Schrödinger, LLC, New York, NY, 
2009) followed by docking studies. The preparation of the modeled Siah2 was 
performed by protein preparation wizard and menadione was prepared using 
the ‘LigPrep’ program and the docking procedure was performed using Glide 
extra precision (XP version 5.5), which produces the least number of 
inaccurate poses and calculates the accurate binding energy of 3D structures of 
a known protein with ligands (Kontoyianni, McClellan et al. 2003; Friesner, 
Banks et al. 2004). Docking studies were carried out using menadione as an 
inhibitor against the modeled SBD of Siah2. The Siah2-menadione ligand 
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complex was used as a reference point in order to identify better drug-like 
molecules that could interact against SBD of Siah2.  
 
2.5 Virtual screening 
A total of 16,908 molecules derived from public databases namely 
Maybridge (14,400, www.maybridge.com), PubChem (Wang, Xiao et al. 
2009) (2438, obtained from Shanghai Institute of Organic Chemistry) and 
Binding (70, www.bindingdb.org), were selected for virtual screening against 
SBD. The in silico structure-based high-throughput virtual screening (HTVS) 
method of Glide, version 5.5 (Schrödinger, LLC, New York, 2009) (Friesner, 
Banks et al. 2004) was used for screening. Before performing HTVS, the 
ligand molecules collected from the databases were prepared using the 
‘LigPrep’ module and were subsequently subjected to Glide ‘Ligand docking’ 
protocol with HTVS mode. 
A grid file was generated using the Receptor Grid Generation protocol 
with centroid at the predicted binding site of the modeled structure. A scaling 
factor of 1.0 was set to van der Waals (VDW) radii for the atoms of residues 
that presumably interact with ligands and the partial atomic charge was set to 
less than 0.25. Ligands were then allowed to dock with the high throughput 
screening (HTVS) mode and all the obtained molecules were subjected to the 
Glide extra precision (XP) mode of docking, which performs extensive 
sampling and provides reasonable binding poses(Friesner, Banks et al. 2004). 
The lead molecules from screening were then tested in silico for their 
pharmacokinetic properties and percent human oral absorption using QikProp 
programme (Jorgensen 2006).  
 
2.6 Cell lines and cell culture 
 Human embryonic kidney 293T (HEK 293T) were grown at 37°C and 
5% CO2 in Dulbecco's modified Eagle's medium (Invitrogen) supplemented 
with 10% fetal bovine serum (FBS) (HyClone), L-glutamine (Invitrogen) and 
pencillin/streptomycin (Invitrogen). 
 T47D, MCF 7 breast cancer cell lines, were kindly provided  by Dr. 
Yong Eu Leong (NUS) and maintained in Minimum Essential Medium Eagle 
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(MEM)  (Sigma Aldrich)  with 1% L-glutamine, 1% penicillin/streptomycin 
and 10% FBS.  
 MDA-MB-231, BT 549, MCF 10A breast cancer cell lines, were 
kindly provided by Dr. Alan PremKumar (NUS) and maintained in Roswell 
Park Memorial Institute 1640 medium (Sigma Aldrich) supplemented with 1% 
L-glutamine, 1% penicillin/streptomycin and 10% FBS. These cell lines were 
obtained ethically from ATCC (Singapore). MCF 10a was cultured in 
Mammary Epithelial Growth Medium (MEGM, Lonza) supplemented with 
growth factors, 10% FBS, 1% L-glutamine and 1% penicillin/streptomycin. 
All cell lines were maintained in a humidified incubator at 37
o
C with 5% CO2 
and sub-cultured according to suppliers recommendations.   
 
2.7 Molecular cloning 
2.7.1 Human plasmid constructs 
 The pcDNA3.1 FLAG-SBD of human Siah2(130-392) and Full-
length(1-394) were constructed by PCR amplification of Siah2 cDNA 
fragments separately from the pCMV-SPORT6 plasmid (Thermo Scientific 
OpenBiosystems) with a HindIII-containing forward primer and an XbaI-
containing reverse primer. The HindIII-Siah2-XbaI fragments was then 
subcloned into the FLAG-pcDNA3.1 plasmid between the HindIII and XbaI 
restriction sites. Similarly FLAG-SBD of Siah1 (90-292) and full-length (1-
292) were constructed as described for Siah2 using the same restriction sites. 
HA-PHD3, HA-Nrf2 and HA-βcatenin plasmids were provided by our 
collaborator Dr. Thilo Hagen. 
 
2.7.2 Bacterial expression plasmid constructs 
 As described above, the gene fragment encoding SBD residues (130-
322) of Siah2, was PCR amplified using the Pfu DNA polymerase (Fermentas) 
with an EcoRI containing forward primer and NotI containing reverse primer 
(1st Base). The amplified gene was ligated into the modified pET-Duet vector, 
next to a pre-inserted bacterial maltose binding protein (MBP), between the 
EcoRI and NotI restriction sites. The second molecular cloning site of the 
vector contained a preinserted bacterial disulfide bond isomerase (DSBC) gene 
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(Pioszak and Xu 2008). This modified vector was a generous gift from one of 
our collaborator Dr. Eric Xu of Van Andel Institute, USA. Full length PHD3 
was PCR amplified using the pcDNA 3.1 PHD3 plasmid as a template and 
then cloned into the modifed  pET-Duet vector as described for Siah2. SBD of 
Siah2 was also cloned in pGEX6P-1 vector with an N-terminal GST tag using 
a BamHI containing forward primer and a XhoI containing reverse primer. 
The list of constructs and primers are given in Table 7 (Appendix 1). 
 
2.8 Transient transfection 
2.8.1 Plasmid transfection 
 DNA plasmids were transiently co-transfected in subconfluent HEK 
293T cells platted in a 60mm plate with GeneJuice Transfection Reagent 
(Novagen). Empty pcDNA3.1 vector was also co-transfected as a control. To 
this end, GeneJuice transfection reagent was first added to serum free DMEM 
media and incubated for 5 min. 1µg of each DNA plasmid was then added to 
the mixture and further incubated for 15 min. The mixture was then added 
dropwise to the cells and returned to the 5% CO2. Cells were lysed 48 hours 
after transfection. 
 
2.8.2 Small-interfering (siRNA) transfection 
 HEK 293T cells were plated at 2 X 10
5 
cells per 6-well plate for siRNA 
transfections. RNAi Max Lipofectamine (Invitrogen) was used as a 
transfection agent according to the manufacturer’s instructions. The following 
predesigned siRNA duplexes (IDT) at final concentration of 20nM were used: 
HSC.RNAI.N005067.12.3, 3'UTR/2 (Siah2 siRNA oligo #1) and 
HSC.RNAI.N005067.12.7, CDS/2 (Siah2 siRNA oligo #2). Lipofectamine 
RNAiMax and respective siRNAs were separately diluted in serum free 
DMEM media for 5 min before mixing together for another 20min of 
incubation at room temperature. The mixture was then added dropwise to the 
cells and returned to the 5% CO2. Cells were lysed three days after siRNA 
transfection.  
 For MCF 7 cells reverse transfection was carried out. siRNA- 
Lipofectamine RNAiMAX complexes as described above, were prepared in 
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opti-MEM reduced serum free media (Invitrogen). This mixture was first 
added to the well and then 1.5 X 10
5 
and 3 X 10
3 
cells per 6-well and 96-well 
were seeded.  Plates were incubated for 72 hours at 37°C in a CO2 incubator. 
 
2.9 Protein isolation and concentration determination 
 At the time of harvest, cells were washed with ice-cold 1X PBS and 
then lysed in 1X MPHER mammalian protein extraction reagent (Thermo 
Scientific). Cell lysates were stored at -80 °C freezer. Protein concentration 
determination of cell lysates was carried out using BSA standard curve assay 
in a 96-well format. Frozen cells were thawed and spun down at 4 °C for 10 
min at 13000 rpm in a microfuge. 1 µl of supernatant was added to 100 µl of 
solution containing 1X Bradford reagent and the absorbance at 595nm was 
read using a Tecan GENios microplate reader (Tecan Trading, Austria). 
 
2.10 SDS-PAGE 
 A 12% resolving gel and 4% stacking gel were casted using 30% 
acrylamide-Bis solution 37.5:1 (2.6% C). Protein lysate was mixed with 1X 
loading dye or Laemmli sample buffer and heated at 95 °C for 5 min. Protein 
samples were spun at 12,000 rpm for 1 min and loaded into wells of SDS-
PAGE gel. Gel containing protein lysate samples were electrophorezed using 
1X running buffer (3.03g Tris base, 14.4g glycine, 10ml of 10% SDS/L) at 
80V for fifteen minutes, followed by 95V for two hours until the dye front 
reached the bottom of the gel. After electrophoresis, the gel was removed and 
proteins were transferred onto a nitrocellulose membrane (AmershamHybond 
ECL, GE Healthcare) in 1X cold transfer buffer (3.1 g Tris base, 14.4 g 
glycine, 20% methanol/L) for overnight at 25 V. 
 
2.11 Immunoblotting and detection 
 The nitrocellulose membrane with proteins was blocked with 5% w/v 
non-fat milk in 1X Tris-buffered saline [0.1% (v/v], Tween-20 (TBS-T) for 1 
hour at room temperature. The membrane was incubated with diluted primary 
antibody in TBST for 1 hour at room temperature or overnight at 4 °C. 
Unbound primary antibody was removed by washing thrice with 1X TBS-T 
43 
for 5 min. Following this, the membrane was incubated with IgG-HRP-
conjugated secondary antibodies at 1:10,000 dilution for 1 hour at room 
temperature. The following antibodies were used to probe the membranes: 
mouse monoclonal anti-FLAG (Sigma) at 1:5000 dilution, rat or mouse 
monoclonal anti-HA (clone 3F10, Roche) at 1:5000 dilution, mouse 
monoclonal anti-β-actin (Sigma) at 1:10,000 dilution, anti-p27 at 1:2000 
dilution. The following primary antibodies required overnight incubation at 
4°C: goat polyclonal anti-Siah2 (Santa Cruz Biotechnology) at 1:500 dilution, 
mouse monoclonal anti-Siah2 (Sigma) at 1:500 dilution. The bound antibodies 
were detected using the detection reagent (Amersham ECL Western Blotting 
System, GE Healthcare. The blot was exposed to X-ray film (Thermo 
Scientific) for different exposure times. 
 
2.12 Co-immunoprecipitaction 
 For co-immunoprecipitation, cells were washed with cold PBS and 
lysed 2 days post-transfection with lysis buffer containing 25mM Tris-
HCL(pH 7.5), 3mM EDTA, 2.5mM EGTA, 20mM NaF, 1mM Na3VO4, 20mM 
sodium β-glycerophosphate, 10mM sodium pyrophosphate, 0.5% Triton X-
100, 0.1% β-mercaptoethanol and Roche protease inhibitor cocktail. lysates 
from transfected cells grown in 60mm plates were precleared by centrifugation 
and were added to beads. Anti-FLAG or anti-HA M2 agarose beads coupled to 
anti-FLAG or anti-HA monoclonal antibody was used to immunoprecipitate 
the FLAG-Siah2 or HA-PHD3. Samples were tumbled at 4 °C for 1 hour and 
washed four times with NP40 lysis buffer containing 20mM Tris, pH7.5, 
50mM NaCl, 0.5mM EDTA, 5% glycerol, 0.5% NP40; and once with buffer 
containing 50 mM Tris, pH 7.5.  
 
2.13 GST pull down  
 For GST pull down assay, GST-fused Siah2 SBD was allowed to bind 
to glutathione sepharose beads (GE Healthcare) for 30 min at 4 °C in binding 
buffer containing 50 mM Tris-HCl buffer, 150 mM NaCl, 1 mM DTT, 5% 
glycerol, 0.1% Triton X-100, pH 8.0. The PHD3 lysate from HEK293T cells 
were allowed to incubate with GST-Siah2 fusion proteins, as indicated, 
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immobilized on glutathione sepharose beads for 1 hour at 4 °C. Controls 
included GST alone, tested for binding to PHD3. After binding, the resin was 
washed three times in binding buffer, and then heated in Laemmli sample 
buffer for 5min at 95 °C. Samples were separately resolved by 12% PAGE and 
Western blotted using anti-HA antibody.  
 
2.14 RNA isolation  
 RNA extraction was carried out using the TRIzol reagent ( Invitrogen). 
Cells were scrapped in 1ml of TRIzol and transferred to 1.7 ml eppendoff 
tubes. The homogenates were then stored for 5 min at room temperature to 
permit complete dissociation of nucleoprotein complexes. They were then 
supplemented with 0.6ml chloroform, vortexed and microcentrifuged at 
13,000 rpm for 15 min. Following centrifugation, the mixture separated into 
middle red phenol-chloroform phase, interphase and organic bottom phase 
respectively. The top colourless aqueous layer was then transferred into a fresh 
tube and equal volume of isopropanal was slowly added to precipitate RNA 
and incubated on ice for 15 min. The samples were then spun down for 10 min 
and the supernatant was discarded. The pellet was washed with 1ml of cold 
75% ethanol. The samples were then centrifuged at 13000 rpm for another 10 
min and the supernatant was removed. The RNA pellet was air-dried and 
dissolved in ultra-pure RNase free water and its concentration was measured 
using NanoDrop ND-1000 spectrophotometer (NanoDrop technologies, 
Wilmington, DE). 
 
2.15 Real-time polymerase chain reaction using SYBR green 
 Real time quantitative RT-PCR was carried out using the one-step RT-
PCR kit with SYBR GREEN (Bio-Rad). PCR was carried out in triplicates for 
each sample being validated. The β-actin gene was used as a control. Primers 
(1
st
 Base) used for Siah2 are as follows and can be found in (Frasor, Danes et 
al. 2005) 
Forward primer: 5-CTATGGAGAAGGTGGCCTCG-3  
Reverse primer: 5-CGTATGGTGCAGGGTCAGG-3 
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2.16 Domain swapping using fusion PCR and mutants 
 A three step fusion PCR procedure was employed to create the fusion 
proteins (Hobert 2002), SBD-Siah1-2 and SBD-Siah2-1 from the wild type 
pcDNA Siah1 and Siah2 constructs described previously. In this procedure for 
generating SBD-Siah1-2, the first round of PCR involved amplifying the first 
100 bp of SBD (1-193 residues) using pcDNA forward primer and Siah1-2 
reverse primer. In the second round of PCR involved amplifying the C 
terminal region of SBD (the remaining 93 bp) using Siah1-2 forward primer 
and pcDNA reverse primer. The final round of PCR was performed using both 
the PCR products that were amplified in the previous rounds as templates and 
with forward and reverse primer of pcDNA.  The final PCR product was gel 
purified and digested with XbaI and HindIII restriction enzymes (New 
England Biolabs). Similarly SBD-Siah2-1 was also prepared as mentioned in 
Table 2. Predigested products were individually ligated with pcDNA, which is 
also digested with XbaI and HindIII restriction enzymes and transformed into 
E. coli DH5α cells. Positive colonies were screened and verified by DNA 
sequencing. 
 SBD-Siah1-2 mutant (Mut) and SBD-Siah2-1 mutant (Mut) were 







Table 2. List of primers and corresponding template used for fusion PCR 
 
 
Gene  Forward Primers Reverse Primers Template 
  Name Sequence Name Sequence  

















product of PCR1 
and PCR2 






 PCR2 Siah2-1 F 5TTGGCCATCAC
TTCATGTTAGTCT









product of PCR1 
and PCR2 
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2.17 Drug treatments and preparation 
 The Five compounds, Compound 1 (ACR#HTS09269SC), Compound  
2 (ACR#SCR01006SC),  Compound 3 (ACR#SCR00073SC), Compound 4 
(ACR#DSHS00977SC), and Compound 5 (ACR#DP01471SC) were 
purchased from Fisher Scientific Pte Ltd, Singapore. Compounds were 
dissolved in DMSO to prepare 200mM Stock.  For all compounds, final 
working concentrations were attained by freshly diluting stock solutions with 
complete medium before use. 
 
2.18 MTS assay  
 The [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4- 
sulfophenyl)-2H-tetrazolium, inner salt] (MTS) assay is a colorimetric method 
for determining the number of viable cells in proliferation or cytotoxicity 
assays. Growth inhibition was measured using the CellTiter 96 Aqueous One 
Solution Assay (Promega, Madison, WI) as recommended by the 
manufacturer. The solution contains MTS compound and an electron coupling 
reagent PES [phenazine ethosulfate]. The MTS compound is bio-reduced by 
mitochondrial enzymes of cells into a colored formazan product that is soluble 
in tissue culture medium. The quantity of formazan product as measured by 
the amount of 490 nm absorbance is directly proportional to the number of 
living cells in culture. Phenol red free culture medium was used. The 
experiment was performed in triplicates.  After 4 hours of incubation under 
standard conditions of 5% CO2 and 37°C, the colour change due to the 
reduction of formazan product (indicative of reduction of MTS) was visible. 
MCF7 cancer cells (4x10
3
 per well) were seeded on 96-well plates in triplicate 
at each dose level. The cells were grown for 24 h prior to treatment. 
Compounds were diluted in DMSO at 200 mM before being further diluted in 
culture medium prior to each experiment. The compounds were added on day 
1 at 0.06 µM, 0.032 µM, 1.6 µM, 8 µM, 40 µM, 200 µM and 1000 µM and 
kept in the media for 72 hours. Absorbance was read in a Tecan GENios micro 
plate reader (Tecan trading, Austria). The signal generated (color intensity) is 
directly proportional to the number of viable (metabolically active) cells in the 
wells. Relative cell numbers can therefore be determined based on the optical 
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absorbance (optical density, OD) of the sample. The blank values (media only) 
were subtracted from each well of the treated cells and controls. 
 
2.19 Protein expression and purification of MBP-SBD-Siah2 and 
MBP-PHD3 
 The pET-Duet construct carrying MBP-SBD-Siah2-6xHis gene at the 
first multiple cloning site (MCS) and DSBC at the second MCS was 
transformed in the E. coli BL21 (DE3) (Stratagene) for protein expression. A 
single colony was picked and inoculated into 100 ml of LB medium 
supplemented with 100 μg/ml ampicillin (Gold Biotech) and allowed to grow 
overnight at 37 °C with continuous shaking.  Subsequently, it was transferred 
into 1 L LB medium supplemented with 100 μg/ml ampicillin and allowed to 
grow at 37 °C until the OD600 was 0.6-0.8 AU. Subsequently, to induce protein 
expression, 0.1 mM isopropyl-1-thio-β-D (-) thiogalactopyranoside (IPTG) 
(Gold Biotech) was added to the culture and grown at 16°C for 16 hrs with 
continuous shaking. Cells from 1 L of culture were harvested by centrifugation 
at 7,000 g for 30 minutes and the pellet was stored at -80 °C. Cell pellet 
obtained was resuspended in 50 ml of lysis buffer containg 50 mM Tris-HCl 
buffer, 150 mM  NaCl, 2 mM DTT, 5% Glycerol, 0.1% Triton X-100  with the 
final pH adjusted to 8.0.  and 1 ml of Sigma protease inhibitor cocktail.  Cell 
suspension was sonicated for 9 min with 1 sec ON and 1 sec OFF pulse. Cell 
lysate obtained was centrifuged at 39,000 g for 30 min to sediment cell debris 
and insoluble proteins; clear supernatant was mixed with 5 ml of Ni-NTA 
(Qiagen) resin pre-equilibrated with lysis buffer and allowed to bind for 1 hr. 
Weakly bound proteins were removed by extensive washing using lysis buffer 
with 10 mM imidazole and later eluted with 250 mM imidazole in lysis buffer. 
To remove the excess imidazole and further purification, amylose affinity 
purification with 3 mL of 50% slurry of amylose resin (New England Biolabs) 
was allowed to bind for 1 hour with Ni-NTA purified MBP-SBD-6xHis with 
gentle shaking using MBP affinity. The wash buffer composition for the 
amylose column is 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, and 5% glycerol 
while 10 mM maltose was added for elution. After affinity chromatography, 
the eluted protein was loaded to a Superdex 200 column (GE Healthcare) 
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equilibrated with 20 mM Tris, 100 mM NaCl, pH 8.0. The purified protein 
was then concentrated using ultra 30 kDa Mol. Wt. cut off Centricon (Merck 
Millipore). 
 Expression of MBP-PHD3 followed almost the same above conditions, 
but during purification in addition to affinity chromatography, ion exchange 
chromatography was carried out prior to gel filtration. In short, the construct 
was transformed into E. coli BL21 (DE3) competent cells and the protein was 
over expressed and first affinity purified using Amylose resin. The protein was 
further purified using an anion exchange Hi-Trap Q-HP (GE Healthcare) 
column, with buffer A: 50 mM Tris and buffer B: 50 mM Tris, 300mM NaCl 
pH adjusted to 8.0. MBP-PHD3 was again purified using a Superdex 200 
column (GE Healthcare) equilibrated with 20 mM Tris, 100 mM NaCl  pH 
8.0. The purified MBP-PHD3 protein was concentrated using ultra filtration 
membrane (Merck Millipore) with 30 kDa molecular weight cut off. All the 
protein purification steps were carried out at 4°C. 
 
2.20 Statistical analysis 
 Siah2 gene expression levels by real time PCR data were analyzed by 
one-way ANOVA, Dunnett's multiple comparison test using the Graphpad 
Prism software. For comparisons, probability values <5% (P < 0.05) were 
considered statistically significant. 
 
2.21 Isothermal titration calorimetry (ITC)  
 The binding affinities and thermodynamic parameters between SBD of 
Siah2 and PHD3 or compounds were studied using isothermal titration 
calorimetry (ITC). The interaction of Siah2 SBD with PHD3 was verified 
using a VP-ITC microcalorimeter (MicroCal) at 25°C in 50 mM Tris buffer, 
pH 8. The cell contained 10 μM SBD. The syringe contained 150 μM of PHD3 
and titrated against SBD of Siah2, which was prepared in the same buffer. 
Samples were first degassed for 15 min and titration was performed using a 
stirring speed of 390 rpm. The initial injection for ligand was 2 μl for 10 s and 
subsequent injections were 10 μl for 10 s with 240 s spacing. Data points were 
fitted using the integrated program ORIGIN (MicroCal) for one-site binding.  
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2.22 Crystallization  
 Crystallization trials were carried for the purified MBP-SBD protein at 
room temperature by hanging-drop vapor-diffusion method using 







CHAPTER 3. IDENTIFICATION OF DRUG LIKE 




 Given its involvement in various cancer and its related signaling 
pathways (discussed in Section 1.8), Siah2 has been suggested as a target for 
developing inhibitors for blocking its activity or abundance (Nakayama, Qi et 
al. 2009). Siah2 regulates HIF-1α by hypoxia response and SPRY2 by RAS 
signaling leading to tumor growth and metastasis.  The SBD is of importance 
in the induction of HIF-1α dependent pathway. However, to date no structural 
or drug targeting information against SBD of human Siah2 is available. 
Homology modeling provides a way of constructing the structure of a protein 
with a "target" from its amino acid sequence and an experimental 3D structure 
of a related homologous protein (the "template"). Herein, we applied 
homology modeling approach to construct the structure of SBD of Siah2 
The inhibition of the Siah2 expression could effectively inhibit 
angiogenesis in tumors.  In this regard, menadione (vitamin K3) has been 
identified as an inhibitor for Siah2 which effectively attenuates hypoxia and 
the MAPK signaling pathway and inhibits melanoma growth in the mouse 
xenograft model (Shah, Stebbins et al. 2009). Targeting a non-catalytic 
substrate has been deemed among the more difficult tasks, although more 
advanced structure-based design holds a better promise.  
 In this study, we present structural information of SBD for Siah2 using 
a homology modeling approach followed by a molecular dynamics simulation 
in order to analyze the stability of this domain. In addition, we predicted the 
binding site of the SBD in order to eventually identify drug-like molecules 
which possessed better binding energies and pharmacokinetic properties for 
this SBD using in silico high throughput virtual screening with menadione as a 
reference ligand, thereby investigating the structural features of SBD of Siah2, 
which may be a novel drug target for inhibitor development studies for cancers 
during hypoxic conditions. The potential specific drug-like molecules obtained 
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from such a screening procedure could serve as inhibitors against SBD of 
Siah2.  
 
3.2 Results  
3.2.1 Generation of SBD of Siah2 by homology modeling 
 The main criteria in homology modeling are the template selection and 
sequence alignment between the target and the template. The PDB ID’s for the 
three template hits that were found for the SBD of Siah2 after performing PSI-
Blast were 1K2F, 2AN6 and 2A25. The 3D-structure of 2AN6 has low 
resolution of 3 Å and there are 13 missing residues in its X-ray structure. 
Although 2A25 seems to be a good template with a resolution of 2.2Å, its 15 
missing residue regions appears as a string in the modeled protein. Therefore, 
1K2F was identified as a promising template having a sequence similarity of 
86% to the SBD with a resolution of 2.4Å
 
and contained no missing residues.
 
Hence, the structure 1K2F was selected as the appropriate template for SBD 
modeling. During modeling the original amino acids positions of SBD i.e. 130 
– 322 were assigned as 1- 193 residues respectively by Modeller 9v7. Hence 
the later positions are assigned for further data analysis. Twenty five models 
were generated and ranked during modeling of SBD against template 1K2F. 
The best ranked model (Fig. 11) was then subjected to evaluation to check the 







Figure 11. Modeled structure for SBD of Siah2 obtained from 
Modeller9v7. The structure is represented in secondary structure mode using 
pymol; the α-helixes, β-sheets and loops are colored in red, yellow and green 
respectively. 
 
3.2.2 Evaluation of the modeled structure 
 The modeled SBD of Siah2 was taken for further optimization and 
validation. The calculated root mean square deviations between the target and 
template structure was found to be 0.324 Å (Fig. 12a). Furthermore, the 
quality of the structure derived from homology modeling was validated by 
calculating the ProSA. z-score which gives the overall model quality by Cα 
positions. The z-score of the target and template were -4.7 and -5.2. Hence the 
quality of the model obtained was validated using ProSA score. Both the target 
and the template models show the similar profiles given in the Fig. 12b and 
12c. 
 The geometric evaluations of the modeled 3D-structure of SBD were 
performed using PROCHECK by calculating the Ramachandran plot (Fig. 
12d) (Table 3). This plot represents the distribution of the Φ and ψ angles in 
each residual of amino acid. The percentage of phi and psi angles in the 
allowed regions is 90% for residues in the core region whereas 0.9% of 





Figure 12. Model validation. (a) Superimposition of modeled Siah2 (target) 
and 1K2F (template) using the 3d-SS tool. In this wireframe diagram, yellow 
color represents the target and green represents the template. (b) z-score of -
4.7 from this graph represents the overall quality of the modeled 3D-structure 
to Siah2. It can be used to check whether the z-score of the input structure is 
within the range of scores typically found for native proteins of similar size. 
Its value is displayed in this plot that contains the z-scores of all 
experimentally determined protein chains in current PDB solved by either X-
ray diffraction or NMR. (c) z-score of -5.1 from this graph represents the 
overall quality of the template 3D-structure (PDB ID 1K2F). When compared 
to Fig. 2b, it was found that the overall quality of the 3D-structures of the 
template and target is highly similar in terms of their corresponding z-scores. 
(d) Ramachandran Plot for the modeled SBD of Siah2. The most favored 
regions are colored red, additional allowed, generously allowed and 






Table 3. Ramachandran Plot statistics on 3D model of SBD of Siah2 









3.2.3 Molecular dynamics simulation of stability 
 The stability of the modeled SBD of Siah2 was assessed by MD 
simulation for 5ns and was used for subsequent docking studies. In addition, 
parameters such as pressure, temperature and total energy were calculated to 
check the stability of the modeled protein with improved steric parameters. 
The analysis of the simulation parameters revealed that the total energy for the 
modeled SBD is -6.74E+5 kJ mol
-1
 and for the template 1K2F is -7.22E+5 kJ 
mol
-1
 (Fig. 13a, 13b). This shows that the target and template does not show 
much variation in terms of their total energy and hence the modeled structure 
was considered to be stable as of the experimentally solved structure of the 
template (1K2F). A pressure bar of 1.0 and temperature of 300K applied to 
both the proteins did not exhibit any significant difference until 5ns. Based on 
these simulation parameters it is evident that the modeled SBD adopted good 
conformational stability that could used for further SBDD.  
 
 
Ramachandran plot statistics for the modeled 
protein 
 core% 90.3 
 allowed% 0.8 
 general% 0.6 
 Disallowed% 0.9 
 Bad contacts 12 
 G factor -0.02 
 Main chain bond lengths -0.17 





Figure 13. Total energy calculated by MD Simulation. The total energies of 
the modeled SBD of Siah2 (a) and the template 1K2F (b) were compared 
using gromacs. This comparison shows that the overall energy of the target 
and template are very similar, so the modeled SBD was considered to be stable 
as the experimentally solved structure of the template (1K2F). 
 
3.2.4 Docking and HTVS screening of compounds 
 The validated and refined model was then used for docking using a 
known functional inhibitor menadione and the complexes were analyzed for 
the putative functional amino acid residues that are involved in hydrogen 
bonding. Prediction of the binding site of SBD was performed using the 
Sitemap in Schrodinger, which yields 13 amino acid residues in the binding 
pocket of SBD for Siah2 (Fig. 14). The predicted binding pocket was validated 
by both blind docking (to examine whether the ligand binds the protein away 
from the predicted binding site) and normal docking (allowing the ligand to 
bind to the predicted binding site) using menadione as an inhibitor against 
Siah2 using Glide (XP). It was observed that 8 of 13 predicted binding site 








Figure 14. Diagrammatic representation of the 13 predicted active site 
residues of SBD. The amino acids in SBD were numbered from 1-193 during 
modeling, whereas the corresponding amino acid residue position for the full 
length protein is also shown which contains the amino acid residues 1-324. 
Yellow color represents the amino acid which is consistent in hydrogen 
bonding formation for all the 5 identified lead molecules, whereas orange 
color represents the other amino acids involved in hydrogen bonding. 
 
 In addition we observed that the amino acid Ser39 (corresponding to 
Ser167 for a full length protein) is involved in hydrogen bond formation with 
menadione during both the docking procedures. This particular binding site 
was utilized for HTVS of compounds from a Maybridge database as one of the 
selection criteria. We next aimed to identify and characterize ligands 
interacting with predicted binding sites of SBD of Siah2. The in silico 
structure-based high-throughput virtual screening (HTVS) method of Glide, 
version 5.5 (Schrödinger, LLC, New York, 2009) (Friesner, Banks et al. 
2004), was used to identify potential ligand molecules that interacted with at 
least one of the residues identified. The binding of ligands to these residues is 
postulated to render competitive inhibition with substrates of Siah2 that 
interact through SBD. 
 
3.2.5 Selection of inhibitors 
 Out of 16,908 molecules from the three public ligand databases, Hits 
were obtained only for Maybridge database.  As a result 1000 potential ligand 
hits were identified based on their pharmacokinetic properties (ADMET). 
Subsequently 156 drug-like molecules were identified based on their glide 
scores better than menadione and compared with its binding conformation; 
eventually 20 lead molecules were selected. Five of 20 drug-like molecules 
were identified based on their hydrogen bond interaction with the putative 
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functional amino acid residue Ser39 with a binding energy ranged from ~ -6 
kcal mol
-1
 to ~ -8 kcal mol
-1
 against Siah2 and their chemical structures are 
presented along with their IUPAC names (Fig. 15), whereas the binding 






Figure 15. Chemical structure of the five lead molecules. Compound 
1(7599): 2',3',4',9'-tetrahydrospiro[piperidine-4,1'-pyrido[3,4-b]indole]; 
Compound 2 (724): (R)-4-methyl-N-(2-oxoazocan-3-yl)-3,4-dihydro-2H-
benzo[b][1,4]oxazine-6-sulfonamide; Compound 3 (4035): 4-methyl-N-((5-
methyl-3-phenylisoxazol-4-yl)methyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-
6-sulfonamide;Compound 4(10746): 2-(2-hydroxyphenyl) quinazoline-4(1H)-
one; Compound 5(7757): 4-oxo-1,4-dihydroquinazoline-2-carbohydrazide. 
Corresponding Maybridge ID's are given in parentheses. 
  
 The binding conformations of these lead compounds towards the 
modeled Siah2 were also analyzed to determine the hydrogen bond 
interactions (Fig. 16). All protein-ligand complexes for these five lead 
molecules possess multiple hydrogen bonds when compared with menadione. 
The short hydrogen bond distance, ranging from ~1.5 to ~2.4 Å, and the 
favourable binding G-scores (-8 to -6 kcal/mol) suggested strong enzyme-
ligand interactions. It is noteworthy that all five lead molecules interacted with 
residue Ser39 in common and their respective glide scores are comparable to 
menadione. The docking results of the final lead molecules against Siah2 are 




Figure 16. Binding poses of the five lead molecules and menadione to SBD 
of Siah2. Panels (a-e) represents the binding pose of lead molecules and (f) 
represents the binding pose of Menadione. The proposed binding mode of the 
lead molecules are shown in ball and stick display and non-carbon atoms are 
colored by atom types. Critical residues of binding are shown as tubes colored 
by atom types. Hydrogen bonds are shown as dotted yellow lines with the 
distance between donor and acceptor atoms indicated. Atom type color code: 
red for oxygen, blue for nitrogen, grey for carbon and yellow for sulfur atoms 
respectively. Ser39 amino acid residue that interacted with the lead molecules 











Table 4. Glide extra-precision (XP) results for the five lead molecules and 
menadione using Schrodinger 9.0. 
 
 a Ligand IDs are of the Maybridge database. b Glide score. c Number of hydrogen bonds formed. 
 
3.2.6 Bioavailability of the lead molecules 
 The drug-like properties of the lead compounds was assessed by 
evaluating their physicochemical properties using QikProp(Lipinski, 
Lombardo et al. 2001). Their molecular weights were < 500 daltons with < 5 
hydrogen bond donors, < 10 hydrogen bond acceptors and a log p of < 5 
(Table 5). These properties are well within the acceptable range of Lipinski’s 
rule of five for the five lead molecules. Further, the pharmacokinetic 
parameters of the lead molecules were analyzed which includes absorption, 
distribution, metabolism, excretion and toxicity (ADMET) using QikProp. For 
the five lead compounds, the partition coefficient (QPlogPo/w) and water 
solubility (QPlogS) are critical for estimation of absorption and distribution of 
drugs within the body, ranged between ~ -0.9 to ~ 2.23 and ~ -0.05 to ~ -3.65, 
while the bioavailability and toxicity were ~ -0.1 to ~ 0.3. Overall, the 
percentage human oral absorption for the compounds ranged from ~ 57 to ~ 
72%. These pharmacokinetic parameters are well within the acceptable range 



















7599 -8.3618 SER39, ILE155 and  HIS156 3 
724 -7.4965 
GLY44, VAL159, CYS40, SER39 and 
HIS156 
6 
4035 -6.7967 SER39, CYS40, HIS156 and VAL159,  4 
10746 -6.5975 SER39 and ILE155 3 
7757 -6.5049 SER39, ILE155 and PRO7 3 


































1.771 -1.251 241.33 -5.708 1 5 3 72.335 
724 
 
0.845 -2.075 339.41 -6.651 3 7 2 74.975 
4035 
 
3.008 -4.930 339.46 -5.765 4 7 1 77.055 
10746 
 
1.842 -3.058 238.24 -5.360 2 4 2 70.148 
7757  -0.523 -1.966 204.188 -5.416 0 6 3 55.280 
Menadione  -0.967 -1.051 198.671 -6.351 4 6 4 57.45 
 
                                         a Ligand IDs are of the Maybridge database.  
                                        b Predicted octanol/water partition co-efficient log p (acceptable range: -2.0 to 6.5).  
                                        c Predicted aqueous solubility; S in mol/L (acceptable range: -6.5 to 0.5 ).  
                                        d Molecular weight ( < 500 daltons).  
                                        e Predicted IC50 value for blockage of HERG K+ channels (acceptable range: below -5.0).  
                                        f Number of metabolic reactions (1 – 8).  
                                        g Hydrogen bond acceptors (< 10).  
                                        h Hydrogen  bond donors (< 5).  




 This study provides the 3D structure of SBD of Siah2 by homology 
modeling approach. Energy minimization and molecular dynamics simulation 
were done to check the stability of the modeled structure. The analysis of the 
homology modeling and MD simulation indicate that the theoretical prediction 
is consistent with the known set of experimental results. This structure was 
used for further insilico HTVS and we have identified five drug-like molecules 
with better binding affinity, when compared to menadione. Compounds are 
screened against the SBD with the aim of inhibiting the activity of Siah2 on its 
substrates targeting via SBD. We mainly hypothesize a competitive binding of 
these compounds to SBD of Siah2 with its substrates.  Also Further analysis of 
the binding conformations of the lead molecules revealed that Ser39 (ser 167 
of full length) residue of SBD may be the key amino acid residue interacting 
with these ligands necessary for the induction of Siah2 activity.  
Yet another possibility of inhibition is also suspected. Siah2 is subjected to 
phosphorylation, which increases its ubiquitin targeted degradation activity 
under hypoxia conditions through MAPK p38 signaling cascade. 
Phosphopeptide mapping or mutational analyses revealed S29 and T24 as 
major sites of Siah2 phosphorylation which are present in the RING domain of 
Siah (Emerling, Platanias et al. 2005; Khurana, Nakayama et al. 2006). The 
study also highlight the possibility that Siah2 may be subjected to 
phosphorylation on other MAPK acceptor sites which are below the detection 
limits used in the experimental condition. We also hypothesize that Ser 39 (Ser 
167 of full length), if found to be one of the phosphorylation site of Siah2, 
could play a role in activity of the compounds.  
 So far the ubiquitin ligases have not been shown to exhibit the catalytic 
activity, but merely to function as scaffolds for ubiquitin transfer, suggesting 
that inhibitors will have to target protein-protein interaction. The identified 
drug like molecules against the SBD of Siah2 may block the interaction 
between Siah2 and its substrates by inhibiting their interaction. We observed 
that these small molecules possessed greater binding affinity, when compared 
to menadione by docking studies. As this study mainly aims to block protein-
protein interaction with no catalytic activity, we hypothesize that these lead 
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drug-like small molecules could serve as inhibitors against Siah2. More 
studies are warranted to reinforce these findings. Since the functionally 
essential role of ser39 (Ser167) is not evident from experimental method, our 
further experimental validation of drug compounds are targeted to inhibit the 





CHAPTER 4. EXPERIMENTAL VALIDATION OF DRUG 




 Siah proteins, evolutionarily conserved E3 RING zinc finger ubiquitin 
ligases, have recently been implicated in various cancers and show promise as 
novel anticancer drug targets. There are various substrates of Siah that have 
recently been reviewed and discussed (House, Moller et al. 2009; Nakayama, 
Qi et al. 2009). Two substrates of Siah2 in hypoxia signaling and cancer have 
been reported, HIPk2 and PHD3. Siah2 has been shown to regulate the 
stability of HIPK2 (Calzado, de la Vega et al. 2009), a transcriptional 
repressor of the HIF-1α gene (Nardinocchi, Puca et al. 2009). HIPK2 directly 
phosphorylates Siah2 resulting in a disruption of the HIPK2/Siah2 interaction, 
thus stabilizing HIPK2 and promoting apoptosis. It  was also reported  that 
chronic hypoxia mainly in rat brain region decreases 2-oxoglutarate (also 
known as α-ketoglutarate dehydrogenase complex (OGDC or KGDHC) 
activity, and Siah2 may function in this process as it targets OGDC-E2 for 
degradation although factors signaling this are not well understood and this 
regulation in not reported in cancer (Habelhah, Laine et al. 2004). Among the 
various substrates of Siah2, PHD3 is well characterized substrate under 
hypoxia condition in cancer. Three PHD proteins have been identified: PHD1, 
2, and 3(Epstein, Gleadle et al. 2001). The association of Siah2 with each of 
the 3 PHDs were examined and the results revealed that PHD3 exhibited the 
highest degree of binding (Nakayama, Frew et al. 2004). Such selective 
targeting was due to the lack of N-terminal extension in PHD3 which are 
present in PHD1 and PHD2 (Nakayama, Gazdoiu et al. 2007). The E3 ligase 
Siah2 preferentially targets PHD3 for degradation under hypoxic conditions 
and thus stabilizing HIF-1α which in turn promotes its transcriptional activity 
(Nakayama, Frew et al. 2004).  Although, all three were found to hydroxylate 
HIF-1α in the in vitro experiments (Bruick and McKnight 2001), in vivo 
PHD2 plays a major role in normoxic HIF-1α regulation (Berra, Benizri et al. 
2003). PHD3 is known to be induced under hypoxia and believed to regulate 
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HIF-1α stability specifically under conditions of low oxygen concentrations.  
Hypoxic condition and the role of PHD1 in regulating Hif -1α is not clear.  
PHD3 can homo- and hetero-multimerize with other PHDs. Consequently, 
PHD3 is found in high-molecularmass fractions that were enriched in hypoxia 
and subsequent degradation by Siah2 (Nakayama, Gazdoiu et al. 2007). 
Inhibiting Siah2 activity with a peptide inhibitor PHYL designed to 
outcompete association of Siah2-interacting proteins reduced metastasis 
through HIF-1α, which is implicated in tumorigenesis, and metastasis. This 
selective targeting of PHD3 is achieved through the SBD. PHYL peptide binds 
to SBD of Siah2 with high affinity and disrupts the PHD3 binding, thereby 
elevating PHD3 levels and reducing HIF-1 α (Qi, Nakayama et al. 2008). 
 
4.2 Results 
4.2.1 SBD of Siah2 alone can independently interact with PHD3 
irrespective of the N terminal Ring Domain 
 In light of the role of Siah2 in regulating PHD3 through SBD, we 
chose this substrate for our further studies. We used coimmunoprecipitation to 
analyze the interaction of Siah2 and PHD3. Two Siah2 plasmid constructs, full 
length and SBD were generated. For this, cells were cotransfected with N-
terminally FLAG-tagged Siah2 full length or SBD construct and HA tagged 
PHD3 or empty vector. Anti-FLAG M2 agarose beads were then used to 
immunoprecipiate the Siah-PHD3 protein complex. The complex was 
analyzed using Western blots with HA antibody to directly compare the 
binding of PHD3 to full length and the SBD of Siah2.  When comparing the 
ratio of PHD3 in the FLAG-immunopreciptates to that in the lysate, a  marked 
enrichment of PHD3 protein was  seen in the immunoprecipitates suggesting 
strong binding of Siah2 towards PHD3 (Fig. 17). Furthermore, it was found 
that the amounts of PHD3 that bound to full length and SBD of Siah2 were 
similar. Taken together, the comparable binding of PHD3 to full length and 
the SBD of Siah2 suggests that under in vivo conditions the substrate binding 
domain alone is sufficient to bind to PHD3. Our results are consistent with the 
data published by Nakayama et al., (Nakayama, Frew et al. 2004), who 
showed that PHD3 is regulated by E3 ubiquitin ligase Siah2 for proteasome-
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dependent degradation. Hence for further experiments, we focused on the 




Figure 17. Coimmunoprecipitation of Siah2 with PHD3. HEK293T cells 
were transfected in 60-mm cell culture plates for 2 days with expression 
constructs for the proteins indicated at the top of panel. The cells were lysed, 
and the lysates were subjected to FLAG immunoprecipitation (IP), as 
described under Materials and Methods. Immunoprecipitates and aliquots of 
the cell lysates were analyzed by Western blotting with the indicated 





4.2.2 GST pull down for SBD of Siah2 with PHD3 
 To confirm the interaction between PHD3 and Siah2 we also carried 
out GST pull down assays. In these assays we used recombinant GST tagged 
SBD of Siah2 and lysates from cells transfected with PHD3. To prepare a 
recombinant GST-SBD, bacterial expression plasmid of GST-Siah2 was made 
in pGEX-6P-1 vector. This expression vector pGEX-6P-1: SBD (130-322) 
was transformed into E. coli BL21 and induced with 0.2 mM IPTG at 18 ˚C 
overnight. The bacteria pellets were harvested, sonicated and lysed in 50mM 
Tris-HCl pH 8.0, 100 mM NaCl, 2 mM dithiothreitol containing a protease 
inhibitors cocktail (Sigma). Similarly, the pGEX-6P-1 expression vector alone 
was expressed as a GST control. After sonication the lysates were pre-cleared 
at high speed centrifugation and the supernatant was used for pull down assay. 
 As shown in Fig 18, the GST pull down experiment was successful and 
in vitro binding of SBD of Siah2 to PHD3 was detected. Therefore, the GST 




Figure 18. GST pull down of SBD with PHD3. GST and GST-SBD proteins 
were immobilized on glutathione-agarose beads and incubated with lysates 
from cells trasfected with PHD3. The samples were then analyzed by western 
blotting using anti HA antibody. 
 
 
4.2.3 Expression and purification of MBP-SBD of Siah2 
 We next intended to analyze the thermodynamics parameters between 
compounds/PHD3 and SBD of Siah2 by ITC experiments. For this 
corresponding proteins were purified. Siah2 with an N-terminal GST was 
expressed for pulldown assays. However attempts to purify and cleave the tag 
leads to protein precipitation and aggregation.  Since the protein yield with 
MBP fusion tag was much higher than when expressed with GST tag, for 
further experiments MBP-SBD-siah2 fusion protein was used. 
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 The soluble SBD, (residues 130-322) of human Siah2 was expressed in 
fusion with the MBP using an oxidizing atmosphere of the in E. coli BL21 
(DE3) competent cells. It was cloned downstream of the MBP tag in  multiple 
cloning site 1 (MCS1) of the modifed pETDuet-1 vector which has a bacterial 
DsbC in MCS2 to assist proper folding of the protein of interest during 
expression. In summary, the final expressed protein was MBP-SBD-Siah2-
6xHis. The protein was purified with affinity chromatography using affinity 
tags at both ends. This was essential to ensure the removal of prematurely 
truncated proteins, which arise due to unwarranted translational stops that are 
common when human proteins are expressed in E. coli. In addition, having 
affinity tags at both ends also prevents co-purification of truncation products, 
which could be formed during or after cell lysis. The recombinant protein was 
first purified using Ni-NTA affinity purification and then followed by amylose 
affinity purification (Fig 19). Secondly, the protein was purified using size 
exclusion chromatography, where the protein eluted as dimer and monomer at 
a molecular weight of 130 and 63 kDa in an S200 column (Fig 20). 
 
 
Figure 19. SDS-PAGE affinity purification profile of MBP-SBD of Siah2. 








Figure 20. Gel filtration profile of purified MBP-SBD of Siah2. (a) After 
affinity purification the elute was passed through Superdex-200 column and 
eluted as three peaks. First peak corresponds to void volume. the second and 
third peak is the dimeric and monomeric SBD of Siah2. (b) Samples from 
three peaks were separated by 12% SDS-PAGE and visualized by Coomassie 
staining. Fusion protein migrated in the gel with an apparent molecular weight 
of 63 kDa. Lanes: 1. Low molecular weight ladder; 2-4. First peak of gel 
filtration elution; 5-9. Second peak of gel filtration elution; 9-12. Third peak of 











4.2.4 Expression and purification of MBP-PHD3 
 Full length and truncated PHD3 with a Histag were cloned in pET-M 
vector and over expressed in BL21 (DE3) cells. However the proteins were 
completely insoluble. The proteins in the inclusion bodies were denatured and 
the attempts to refolding yielded, a protein precipitation (Fig. 43 Appendix 
2.1). Hence we moved on to the MBP tag which aids in the solubility and 
purification of PHD3. Similar to the expression of MBP-Siah2, MBP-PHD3 
expression was carried out (Fig 21) and purified in three steps: affinity 
purification using amylose resin, anion exchange chromatography (the pI of 
MPB-PHD3 is 6) (Fig 22) and size exclusion chromatography. The MBP-
PHD3 protein eluted as a monomer in the size exclusion chromatography, 
corresponding to its molecular weight of 65 kDa. The eluted fractions of gel 
filtration show the protein is about 95% pure, (Fig 23).  
 













Figure 22. The ion-exchange chromatography profile of PHD3. (a) The 
blue line indicates the UV reading when samples are passed out of the column 
and the brown line indicates the concentration of high-salt buffer added into 
the column. (b) SDS-PAGE gel showing the FPLC fractions of the eluted 
protein run on an anion exchange column. The SDS-PAGE gel verified that 
PHD3 is found in Peak 3. Lanes 2 to 3 correspond to Peak 1, lanes 4 to 5 











Figure 23. Gel filtration profile of purified MBP-PHD3. (a) After ion 
exchange the fractions were pooled and passed through Superdex-200 column 
for further purification. MBP-PHD3 eluted as two peaks. First peak 
corresponds to void volume. The second elutes as a monomeric PHD3. (b) 
Samples from two peaks were separated by 12% SDS-PAGE and visualized 
by Coomassie staining. Fusion protein migrated in the gel with an apparent 
molecular weight of 65 kDa. Lanes: 1. Low molecular weight ladder; 2-8. First 
peak of gel filtration elution; 9-10. Second peak of gel filtration elution. 
 
 The purification of both MBP-SBD and MBP-PHD3 resulted in highly 
pure proteins, which were used for ITC experiments and crystallization 
attempts. The identity of the protein was verified by Mass spectrometry (MS) 





4.2.5 ITC analyses 
 Inhibitors have high affinity towards Siah2 compared to PHD3 
 Interactions between SBD of Siah2 and the compounds and PHD3 
were studied using ITC experiments. ITC is very useful in drug development, 
mainly to determine the relative affinities of a ligand that can bind to a protein 
with one or more different and specific binding sites. The thermodynamic 
parameters of these interactions are shown in Table 6. All the ITC experiments 
were performed with the titration of ligands at 150 μM into SBD at 10 μM in 
the cell under same buffer conditions. All  reactions were exothermic in nature 
as shown in Fig. 24 and the upper panels show the raw ITC data of each 
injection. The peaks were normalized to the ligand-protein molar ratio and 
were integrated as shown in the bottom panels. Solid dots indicate  
experimental data, and their best fit was obtained from a non-linear least 
squares method, using a one-site binding model depicted by a continuous line. 
 PHD3, compound 1 and compound 5 bind to SBD in 1:2 ratio (N = ~2) 
at two binding sites with nearly the same thermodynamic properties (Fig. 24a, 
b, f).  However compound 2 and compound 3 bind in 1:1 ratio at one binding 
site (Fig 24c, d).  For compound 3, the inflection point in the calorimetric 
isotherm occurs near the molar ratio of 0.6, suggesting only half of the binding 
site is occupied by the compound (Fig 24d). Compound 4 shows a non-
stoichiometric binding profile with N = 0.05 and from the best fit values, the 
standard error was large (data not shown) suggesting the initial heat changes 
are unlikely to be significant and suggests no binding (Fig. 24e). Compared to 
the compounds, the heat released when the substrate (PHD3) was titrated 
against the SBD of Siah2 was observed to be large as it a protein-protein 
interaction. The binding affinities of compound 1 and 5 were observed to be 
four fold stronger than that of the binding affinity of Siah2-SBD-PHD3.  As 
control, MBP-SBD of Siah2 was titrated against no ligand or substrate (Fig. 
24g). 
 In addition, all observations were further analyzed by enthalpy and 
entropy changes (Table 6). The negative Gibbs free energy change for SBD-

















Figure 24. ITC data for SBD with compounds and PHD3. (a) SBD-PHD3 
titration. (b) SBD-Cpd 1 titration. (c) SBD-cpd 2 titration. (d) SBD-cpd3 
titration. (e) SBD-cpd4 titration. (f) SBD-cpd5 titration. (g) SBD-Control. The 
upper panels show the injection profile after baseline correction and the 









Table 6. Thermodynamic parameters for interaction between SBD of Siah2 and PHD3 or compounds 
(“-” represents “no binding”) 
 










PHD3 2.07  0.029 2.30 0.339 4.34 -7.74 0.177 3.15 -10.89 
Cpd 1 1.805±0.050 7.02 ±0.801 1.42 -2.23±0.120 5.72 -7.95 
Cpd 2 1.06  0.081 3.28       3.04 -2.11       6.62 -8.73 
Cpd 3 0.649  0.073 1.28        7.8 -3.95 0.837 1.18 -5.13 
Cpd 4 - - - - - - 
Cpd 5 1.785       9.34 0.485 1.07 -6.14       6.02 -12.16 
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4.2.6 Compounds partially decrease SBD interaction with PHD3 
We used both coimmunmoprecipitation and GST pull down assays to 
study the effect of the compounds on the interaction between the SBD of 
Siah2 and PHD3. We hypothesized that the identified small molecules would 
bind to the binding sites of SBD and would reduce or prevent Siah2 binding to 
its substrate. From the docking screen of more than 16,000 compounds in the 
May bridge library the top scoring 5 chemicals that were predicted to bind to 
the ligand binding pocket of SBD with high affinity were tested for their 
ability to inhibit the binding interaction between the Siah2 SBD and PHD3.  
 
4.2.6.1 Coimmunoprecipitation of SBD with PHD3 in the presence of 
compounds 
 Coimmunoprecipitation of Siah2 SBD and PHD3 was carried out in 
the presence of the identified lead compounds to test their efficacy. As 
mentioned earlier, the FLAG tagged SBD and HA tagged PHD3 proteins were 
co-transfected in the HEK293T cell line. After 40 hours of transfection, the 
cells were treated with the inhibitors at a concentration of 100 µM for 4 hours. 
The cells were then subjected to lysis and immunoprecipitated with FLAG 
beads and analyzed by western blot using an anti-HA antibody. Compounds 1, 
2, 3 and 5 were found to partially decrease the SBD coimmunoprecipitation 








Figure 25. Coimmunoprecipitation of SBD with PHD3 in the presence of 
the compounds. HEK293T cells were transfected in 60-mm cell culture plates 
for 2 days with expression constructs for the proteins indicated at the top of 
each panel. four hours before the lysis, cells were treated with 100 µM of each 
compounds seperately and then coimmunoprecipitates of SBD with PHD3 was 
analyzed. The cells were lysed, and the lysates were subjected to FLAG 
immunoprecipitation (IP), as described under materials and methods. (a) 
represents the immunoprecipitates of SBD with PHD3 in the presence of 
inhibitor. Compound 1, 2, 3 and 5 found to have a subtle level of inhibition 
between the SBD and PHD3 complex. (b) represents the expression levels of 






4.2.6.2 GST pull down of SBD with PHD3 in the presence of compounds 
 We next performed the GST pull down assay in the presence of 
compounds to test the effect of the compounds in the in vitro binding of SBD 
of Siah2 with PHD3. SBD was, expressed as the GST fusion protein in 
Escherichia coli. Equal volume of bacterial protein supernatants (derived by 
centrifugation of 1 litre cultures depending on the relative expression level of 
recombinant protein) were incubated with PHD3 in the presence of a given 
compounds at 100 μM concentration. Among the compounds only compound 
5 showed marked activity in suppressing Siah2 binding to PHD3 (Fig. 26a). 
As pre incubation of compounds with Siah2 was not performed previously, we 
intended to check whether pre incubation of the compounds with Siah2 prior 
to the addition of PHD3, would result in a greater inhibitory effect. Hence, we 
performed the pull-down assay with 3 different drug concentrations: 200 μM, 
1 mM and 2 mM, where the compounds were allowed to pre incubate with 
SBD prior to binding to PHD3. Based on the initial pulldown data, 
Compounds 1, 3, 5 were chosen for pull down in a dose dependent manner. 
Compound 5 was effective in inhibiting the interaction at 200 μM and 1mM 
but not at 2mM. The lack of effect at 2mM may be due to low solubility. 
Compound 1 was found to partially inhibit the interaction at the same level in 
all the three doses. Compound 3 partially inhibited the interaction at the higher 
concentrations of 1mM and 2mM (Fig 26b). From this data, among the five 









Figure 26. GST pull down of SBD with PHD3 in the presence of 
compounds. (a) Hek293T cells transiently over expressing PHD3, were 
harvested and the cell lysates were subjected to the GST-SBD or GST alone 
pull-down assay (materials and methods) in the absence or presence of 
Compounds at the indicated concentration. Only Cpd 5 has visible reduction in 
binding of SBD of Siah2 with PHD3. (b) GST pull down of SBD with PHD3 
in the presence of compounds in a dose dependent manner. Hek293T cells 
transiently over expressing PHD3, were harvested and the cell lysates were 
subjected to the GST-SBD or GST alone  pull-down assay (as described in 
materials and methods) in the absence or presence of Compound 1, 3, and 5 at 
the three different concentrations. Cpd 5 shows consistent and marked 
reduction in inhibition. (c) commasive blue staining to show the expression of  






4.2.7 Basal level expression of Siah2 in breast cancer 
 In order to further analyze the antiproliferative and cytotoxicity of the 
compounds in cell lines, we chose selected breast cancer cell lines.  
 Studies of Siah2 have shown that the E3 ligase functions as an 
oncogene in  animal models  and patient cohort studies of human breast cancer 
(Moller, House et al. 2009; Behling, Tang et al. 2011; Chan, Moller et al. 
2011; Wong, Sceneay et al. 2012) .  The expression of Siah2 in breast cancer 
cell lines has not been well characterized as most studies are based on Siah2 
staining in cancer tissues and the normal counterparts. Two cell line based 
studies in breast cancer drew our interest in analyzing the expression levels of 
Siah2 prior to test the activity of the compounds. The first study reported that, 
estrogen increases Siah2 levels in estrogen receptor ER positive breast cancer 
cells. This resulted in degradation of the nuclear receptor corepressor 1 (N-
CoR) and a reduction in N-CoR–mediated repressive effects on gene 
expression, thus promoting cancer growth (Frasor, Danes et al. 2005). In 
contrast to this, another study reported the higher level of Siah2 expression in 
the ER negative cell line (MDA-MB2 31) (Sarkar, Sharan et al. 2012). In this 
cell line Src and Siah2 mediated the degradation of C/EBP, a tumor 
suppressor protein. Hence we chose two ER positive breast cancer cells 
(MCF7 and T47D) and two ER negative breast cancer cells (MDA-MB231 
and BT549) and one normal breast epithelial cell MCF 10A to compare the  
expression levels of Siah2 in these cell lines and subsequently to check the 
activity of the compounds in the same. 
 The Siah2 m-RNA expression levels in these cell lines were analyzed. 
To quantify the mRNA levels, we used real time PCR and the primers were 
validated (Fig. 27). Our result shows that the expression level was elevated in 
ER positive MCF7 cells consistent with the finding that estrogen increases 
Siah2 activity in ER positive cells.  The ER positive T47D cell line also shows  
significant difference compared to the normal cell line (Fig. 28). In conclusion 
these results are consistent with an important role of Siah2 in breast cancer. 
Given that Siah2 showed the highest expression in MCF7 cells we used this 






Figure 27. Agarose gel showing the size of single PCR products generated 
by Siah2 gene-speciﬁc primers for q-PCR. cDNA from HEK293T cells 
were used as template. 100 bp DNA ladders were loaded to identify the base-
lengths of PCR products. Sizes of PCR products correspond to the sizes 
obtained from primer validation data.   
 
 
Figure 28. mRNA expression analysis of Siah2  in breast cancer cell lines. 
Total RNA extracted from all five breast cell lines was subjected to 
semiquantitative RT-PCR.  Experiments were repeated in triplicates. * denotes 









4.2.8 siRNA mediated gene silencing 
 We next wanted to determine the protein concentration of Siah2 in 
different cell lines. Gene knock down studies were carried out for evaluating 
the specificity of the compounds for Siah2 and also to validate the antibody. 
The Siah2 gene was knocked down in HEK293T and MCF 7 cells using 
siRNA and quantitative reverse transcription–PCR was performed to 
determine the extent of knockdown of Siah2. Two SiRNA’s, one targeting the 
3′ UTR region and the other targeting the coding region were used. From the 
two dsiRNA oligos tested, oligo #1 and oligo #2 were found to efficiently 
down-regulate Siah2 mRNA levels (Fig. 29). 
 The selectivity and the specificity of siRNA knockdown can be 
verified by rescue experiments. Our results clearly show that over expression 
of Siah2 was not rescued by siRNA 2 and thus both endogenous and over 
expressed Siah2, is successfully abrogated by siRNA2. However, siRNA1 
completely rescued  Siah2 as it targets the 3 UTR region (Fig. 30). 
 
 
Figure 29. Validation of knockdown of Siah2 in HEK293T and MCF7 cell 
lines. Cells were transfected with indicated oligos for 72 hours and were 
harvested for RNA extraction. Real time-PCR was performed with Siah2 







Figure 30. Rescue experiments using the Siah2 full length constructs. 
HEK293T cells were cotransfected with indicated siRNA or control siRNA 
oligos, together with the expression vectors: Flag-tagged Siah2, or the empty 
vehicle vector; At 48 h post-transfection, cell lysates were analyzed by 
Western blotting with anti FLAG ab and actin as a loading control. 
 
4.2.9 Endogenous Siah2 protein expression and antibody validation 
 Goat polyclonal anti-Siah2 (N-14) (sc-5507; Santa Cruz 
Biotechnology) antibody was used to identify the endogenous Siah2 protein 
expression levels in all four breast cancer and one normal  breast epithelial cell 
lines. However, the observed  non specific binding made it difficult to identify 
endogenous Siah2 expression. Also differences in protein (from the suspected 
respective molecular weight band) (Fig. 31a) and mRNA expression patterns 
of Siah2 were observed. In this regard, Siah2 protein was tested for its stability 
using cyclohexamide, a protein synthesis inhibitor. Over time there was no 
degradation of the protein as detected by the antibody (Fig. 31b). Thus we 
validated the antibody to check its specificity for Siah2 and to confirm the 






Figure 31. Analysis of endogeneous Siah2 protein expression and test for 
its stability. (a) The cell lines were cultured, harvested, and analyzed by 
Western blot analysis with Siah2 antibody from Santa Cruz and actin (as a 
loading control). Rasmos lysate positive control for Ab1 was also used. (b) 
MCF7 and T47D cells were treated with 40 μM cycloheximide (CHX), a 
protein synthesis inhibitor, and were lysed at time points 0, 2, 5 and 8 hr. No 
change in stability of Siah2 protein detected by Ab1. As a control, an unstable 
protein p27 was analyzed for its stability by CHX. 
  
 In order to determine the specificity of the antibody we analyzed both 
the endogenous and ectopic expression of Siah2 in the presence or absence of 
siRNA oligos. There was no difference in expression levels observed in both 
endogenous and ectopic Siah2 (Fig. 32). The results apparently show the 
inability of the antibody to detect the Siah2 protein. We also tried validating 
another antibody, Mouse monoclonal anti-Siah2 (S7945; Sigma). 
Unfortunately even this antibody was also not able to detect Siah2 protein 
expression. Antibody IP was carried out for both the antibodies simultaneously 
along with a control antibody to check whether they could detect the Siah2 
protein in immunoprecipitates (data not shown). For these reasons we could 







Figure 32. Antibody validation using siRNA oligos. HEK293T Cells were 
transfected with negative control or Siah2 siRNA for 3 days and with FLAG-
Siah2 for the last 2 days. Cells were lysed and cells lysates were analyzed by 
Western blotting with the indicated antibody. Antibody could not detect the 





4.2.10 Effect of Compounds on Cell Viability 
 MTS proliferation assay was used to analyze the anti proliferative and 
cytotoxic activity of all the five compounds in MCF7 cells. Viable cell masses 
at the time of drug addition (time 0), and following 72 hours of drug exposure 
were determined. For this, serial dilutions of these compounds were prepared 
at a final concentration of   0.064, 0.32, 1.6, 8, 40, 200 and 1000 µM 
respectively. The compounds and untreated control (UnC) were tested in 
triplicate. To investigate the effect of compounds on the growth of MCF 7 cell, 
the cells were treated with the compounds of indicated concentration and 
incubated for 72h. The absorbance measures were normalized to that of 
control untreated cells at 72h. Anti-proliferative and cytotoxicity, elicited by 
all 5 compounds in the MCF 7 cell line were obtained as shown in Fig 33. 
From this data we observe that the all compounds exhibit varied activity on 
MCF7 cells. As shown in Fig. 33, marked reduction in the cell growth was 
observed in the cell treated with compound 1 after 72 h treatment. This 
inhibitory effect of compound 1 is observed between 1 and 40 μM.  On the 
other hand compound 4 has cytotoxic effect at low concentration and as the 
concentration increases cytotoxicity decreases. This could be because of poor 
compound solubility at high concentrations.   No cytotoxicity or anti-
proliferative activity was observed in cells treated with the compound 2. 
However, compounds 5 and 3 showed minimal inhibition of growth when 
compared to the UnC.  These results indicate that the compounds have limited 
activity in cell line. These observations frame critical considerations to focus 
on the other structural analogues or by side chain modifications, which could 











Figure 33. Cell proliferative effects of compounds in MCF7 cell line. 
Antiproliferative or cytotoxicity effects of all five compounds in MCF 7 cell 
was analyzed by MTS assay by measuring the number of viable cells. The 




4.2.11 Analysis of the specificity of the compound 1 for Siah2 in MCF7 
cells 
 Since compound 1 possesses effective anti proliferative activity, the 
compound was chosen to study the specificity of compounds for Siah2. To 
determine whether the anti-proliferative and cytotoxic activity of compound 1 
is dependent on the presence of Siah2, we repeated the assay in MCF 7 cells 
with siRNA mediated Siah2 knock down. Since the maximum inhibition was 
observed at a concentration of 40 µM, we used this concentration for the 
knock down studies. However, there was a similar growth inhibition in Siah2 
knock down compared to control cell. This result suggests that compound 1 
has low specificity in cells and exerts Siah2 independent effects specificity of 




Figure 34. Specificity of Compound 1 to Siah2 in MCF 7 cell line. Cell 
proliferation of MCF7 cells at 40 µM in the presence of non specific and 







4.3.1 Advantages  
 In our second study, we addressed one of the important criteria which 
determine the medical value of a candidate drug, 'specificity'. The 
physiological effect of a drug should be defined to an extent. It has to 
specifically bind to a target protein in order to minimize undesired side-
effects. However, efficacy is not always a result of lack of specificity alone but 
also could be from the response body to drug and related regulation of 
malfunction. Molecular level specificity includes two independent 
mechanisms. First the drug has to bind to its substrate with suitable affinity 
and second it has to either stimulate or inhibit the regulation of its target 
protein. Both mechanisms are mediated by a variety of interactions between 
the drug and target.  
 The results from our biochemical, biophysical and cell-biological 
assays indicate that the novel compounds identified through computational 
screening have partial selective inhibitory property for the SBD of Siah2 in the 
in vitro and in vivo binding assays. We characterized the thermodynamic 
parameters of the interaction of the SBD of Siah2 with the substrate PHD3 by 
identified test compounds. We also analyzed the anti-proliferative, cytotoxic 
profile and specificity of the compounds. The relationship between in vitro 
affinity and in vivo inhibition constants is reported in Appendix 3. Although 
the molecular details of the specificity of the compounds towards SBD 
remains unclear, our study provides the strategy of identifying small molecules 
through SBDD and validation for its specificity through in vitro and cell based 
binding assays.    
. 
4.3.2 Limitations 
 There could be various reasons for the partial activity of the 
compounds. The first reason is drug solubility. Although the computational 
predictions of pharmacokinetic and bioavailability properties of all these 
compounds, falls under acceptable ranges, there could be some issues with 
poor drug solubility. The solubility proﬁle of a substance is required to 
identify the potential issues in drug precipitation in vivo. With the aid of 
advancement in combinatorial and medicinal chemistry, a slight chemical 
91 
modiﬁcation of a molecule can lead to enhancement in solubility (Amidon, 
Lennernas et al. 1995). In addition to solubility, factors such as trans-
membrane delivery or cell uptake efficacy, bio-stability, and nonspecific 
absorption or binding by serum or cellular proteins may contribute to better 
efficacy in cells. The reason for not including menadione as one of the control 
is because of their potential toxicity in human use which is banned by FDA. 
Since the compounds are screened against SBD, there was a limitation to 
measure the activity of compounds in degrading PHD3 as it requires full 
length protein. 
  The Siah protein levels may be differentially regulated because of 
stability as these proteins are reported in auto ubiquitination  (Hu and Fearon 
1999; Depaux, Regnier-Ricard et al. 2006),  and hence this may limit the 
availability of the proteins to bind to the target or compounds. We could not 
confirm this hypothesis since we were not able to detect the endogenous 
protein expression levels because of poor antibodies. 
 Another important reason is cross reactivity. Due to high sequence 
similarity between the Siah1 and Siah2 SBD, it is suspected the identified drug 
compounds could also cross react with Siah1. Our initial screening of the 
compounds also ignored Siah1 specificity. In support to this, most of the 
tumor suppressor role of Siah1 was identified in breast cancer. Hence we 
hypothesize that the activity of compounds in the Siah2 knockdown cells may 
likely be affected due to the cross reactivity with Siah1.  
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CHAPTER 5. IDENTIFICATION OF CRITICAL RESIDUES 
INVOLVED IN SUBSTRATE SPECIFICITY OF SIAH2 
 
5.1 Introduction 
 Siah1 and Siah2 share a highly conserved protein sequence which 
reflects similar functional roles in a few instances (Confalonieri, Quarto et al. 
2009; Kramer, Stauber et al. 2013).  However, there are notable differences in 
the expression of Siah1 and Siah2. Siah1 is induced by p53 upon genomic 
stress (DNA damage), while Siah2 is induced by hypoxia (Matsuzawa, 
Takayama et al. 1998; Qi, Nakayama et al. 2008).  
 Siah1 and Siah2 have a number of substrates in common but there are 
some proteins targeted by one and not the other (Qi, Kim et al. 2013), which 
might affect different cellular signaling networks. For example, DCC is 
regulated by both Siah1 and Siah2 (Hu, Zhang et al. 1997). In some cases, 
substrates are targeted for degradation by solely one Siah member, for 
example TRAF2 is targeted for proteasomal degradation by Siah2 but not 
Siah1 (Habelhah, Frew et al. 2002). In most publications however, only one 
Siah family member is analyzed and often it is not clear which Siah family 
member is under scrutiny. Thus, further investigation is needed to determine 
whether or not the identified substrates are regulated by each of Siah isoform. 
 Animal model system uniformly supports an oncogenic role of siah 
proteins in various cancers, whereas cell based and patient cohort observations 
describe Siah2 as tumor promoter and Siah1 as tumor suppressor in most cases 
(chapter 1). A recent review highlights the different roles of Siah proteins, 
highlighting the necessity for more in-depth understanding of both Siah1 and 
Siah2 protein function (Wong and Moller 2013). In spite of this, most of the 
studies reported, do not discriminate Siah1 and Siah2 expression in same 
cancer type and therefore, are not conclusive whether both or only one is a 
valuable prognostic marker.  
 A report investigating the physiological functions of Siah1 and Siah2 
genes by generating knock-out mice demonstrated that Siah1a knockout mice 
are sub viable and growth retarded whereas Siah2 knock-out mice are 
completely viable. However Siah2 Siah1a double mutant mice die at birth 
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(Frew, Hammond et al. 2003). This supports the notion that Siah1 and Siah2 
proteins have both distinct and overlapping functions, but their exact roles are 
still not clear. Because of these differences, they are also thought to have 
unique roles. 
 Hence, we decided to investigate the critical residues involved in 
substrate specificity of Siah2 with respect to Siah1, which will allow us to gain 
a better understanding of their unique roles. In order to identify critical 
residues, we verified the binding studies with other Siah substrates; β catenin 
(DNA damage) and Nrf2 (Hypoxia) in addition to PHD3 (Hypoxia). 
 β-catenin is a multifunctional protein that plays an essential role in the 
transduction of Wnt signals. Studies reported that Siah-1 mediates a β-catenin 
degradation pathway linking p53 activation to cell cycle control with the 
interacting protein. However, this degradation is mediated through a complex 
including Ebi, Sip and APC, which facilitates the degradation of β-catenin in a 
p53-dependent manner (Liu, Stevens et al. 2001; Matsuzawa and Reed 2001). 
 On the other hand it is reported that Siah2 mediates PHD3 degradation 
under hypoxic conditions.  It is also highlighted that PHD3 might require an 
unknown adaptor protein for Siah2 mediated degradation (Nakayama, Frew et 
al. 2004). However, our binding studies show the direct binding of Siah2 with 
PHD3 (Fig 14). So we also analyzed the direct binding of Siah isoforms with 
β-catenin along with PHD3 to gain more insights about substrate specificity. 
 Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a key 
transcriptional activator of antioxidant-response elements (AREs) and a 
central regulator of the induction of antioxidant responsive enzymes. Under 
normal conditions, Nrf2 is constantly degraded through the ubiquitin-
proteasome pathway in a Keap1-mediated manner (McMahon, Itoh et al. 
2003). It has been very recently reported that Nrf2 is regulated by Siah2 under 
hypoxic condition and the direct binding of Siah2 with Nrf2 was also reported 
(Baba, Morimoto et al. 2013). In this respect our final findings were also 
verified with Nrf2 to confirm the role of identified critical residues. 
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5.2 Results  
 In general, the roles of Siah1 and Siah 2 are expected to overlap and 
the unique features of each protein are not clear. We tried to investigate the 
Siah1-PHD3 interaction in order to know is there any significant difference in 
the level of binding of PHD3 with Siah1 and Siah2. In this respect, a FLAG 
tagged Siah1 expression plasmid in pcDNA3.1 was generated. Cloning was 
confirmed and coimmunoprecipitation studies were carried out in HEK293T 
cells. 
 
5.2.1 Siah1-PHD3 interaction 
 It has been reported that Siah2 is more efficient than Siah1 in 
destabilizing over expressed PHD3 (Nakayama, Frew et al. 2004). Another 
study reported that Siah1 (human) and Siah1a (mouse) reduced PHD3 protein 
levels similar to Siah2 but Siah1a M180K mutant did not alter the PHD3 
protein levels suggesting that the Siah substrate-binding groove is important 
for PHD ubiquitination and degradation (Moller, House et al. 2009). However 
no direct binding of Siah1 with PHD3 has been reported so far.  
 In this regard, we first investigated the interaction of Siah1 with PHD3 
(Fig 35). To this end, HEK293T cells were cotransfected with the 
corresponding expression constructs, followed by immunoprecipitation using 
an anti-flag antibody. Interestingly we observed a weak interaction of SBD of 
Siah1 with PHD3 when compared to Siah2 with PHD3 (Fig 35a). A 
subsequent reciprocal immunoprecipitation assay was also performed to check 
the binding of both full length and SBD of Siah1 with PHD3 as it shows weak 
binding with the FLAG immunoprecipitaion of the SDB of Siah1. For this, 
HEK293T cells were cotransfected with the corresponding expression 
constructs, followed by immunoprecipitation using an anti-HA antibody. HA 
immunoprecipitation of PHD3 exhibits no binding of PHD3 with Siah1 (Fig 
35b). Hence the data obtained by both immunoprecipitation and reciprocal 
immunoprecipitation assays, suggest the difference in binding levels between 







Figure 35. Association of Siah1 with PHD3. HEK293T cells were transfected in 60-mm cell culture plates for 2 days with expression 
constructs for the proteins indicated at the top of panel. The cells were lysed. (a) The lysates were subjected to FLAG-IP and aliquots of the cell 
lysates were analyzed by western blotting with the anti-HA antibodies. Weak binding of SBD of Siah1 with PHD3 was observed compared to 
Siah2. (b) The lysates were subjected to HA-IP. Immunoprecipitates and aliquots of the cell lysates were analyzed by Western blotting with the 
anti-FLAG antibodies. Both the Full length and SBD of Siah1 did not show binding with PHD3 by HA-IP (reciprocal immunoprecipitation). The 
membrane was also immunoblotted using anti-FLAG or anti-HA antibody for the detection of protein in the lysates. 
a b 
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5.2.2 SBD of Siah1 and Siah2 region swapped to obtain chimeric forms 
 Amino acid residues 90-282 (193) and 130-322(193) contribute to the 
SBD of Siah1 and Siah2, respectively. In order to avoid confusion residue 
numbers for both the SBD are labeled as 1-193 (Fig. 36). To identify which 
region of SBD favours the binding, region swapping using fusion PCR was 
performed as described in Materials and Methods, in which residues from 101-
193 region of Siah1 was swapped with the corresponding region of Siah2 and 




Figure 36. Diagrammatic representation of SBD of Siah1 and Siah2. SBD 
of Siah1 and Siah2 (Top panel). SBD of Siah1-2 and Siah2-1(bottom panel). 
Corresponding full length residue numbers are given in given in parentheses. 
 
 
5.2.3 Binding of wild type (WT) and chimera SBD's with substrates 
 Next, we investigated the interactions of the SBD of Siah1-2 and 
Siah2-1 with PHD3. Along with this, direct interaction of β-catenin with the 
WT and chimeric Siah isoforms were also analyzed using 
coimmunoprecipitation.  To this end, HEK293T cells were cotransfected with 
the corresponding expression constructs, followed by immunoprecipitation 
using an anti-FLAG antibody. In these experiments, only WT SBD of Siah2 
interacted with PHD3, whereas Siah2-1 interaction was markedly reduced 
compared to WT SBD, suggesting the importance of the region 101-193 in 
binding. Interestingly Siah1-2 did not exhibit any binding to PHD3 even 
though it contains the swapped region of Siah2 (Fig 37). These results suggest 
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that both regions of SBD 1-100 and 101-193 are equally important for binding 
with substrate. We observed no direct binding of β-catenin with both SBDs of 
(Fig 37). This study supports the finding that Siah1 mediates β-catenin 
degradation through SIP or APC by UV-induced DNA damage whereas Siah2 
causes PHD3 degradation under hypoxia conditions and suggests that the 





Figure 37. Association of wild type and chimeric SBD's of Siah with its 
substrates. HEK293T cells were co-transfected in 60mm plate with 
pcDNA3.1 containing HA-β-Catenin, HA-PHD3, FLAG-SBD-Siah2,FLAG 
SBD-Siah1, FLAG-SBD-Siah1-2, FLAG SBD of Siah2-1 as indicated in the 
top of panel. Forty eight hours after transfection, the cells were lysed and cell 
lysates were subjected to FLAG immunoprecipitation and then immunoblotted 
using anti-HA antibody. We also immunoblotted using anti-FLAG antibody 
for the detection of protein in the lysates (bottom panel). 
 
 
5.2.4 Identification of critical residues unique for Siah2 
 In order to identify the critical residues in SDB of Siah2 which confer a 
substrate specificity, sequence alignment was performed to identify the unique 
amino acids in which Siah1 and Siah2 differ. Pairwise sequence alignment 
was performed by the EMBOSS Needle tool, which creates an optimal global 
alignment of two sequences using the Needleman-Wunsch algorithm (Rice, 
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Longden et al. 2000). From the alignment of SBD of the Siah isoforms, twenty 
six amino acids are different while the remaining residues are identical or 
conserved (Fig. 38). Out of 26, ten amino acids are found be less similar or 
different, based on amino acid properties. Hence we narrowed to 10 amino 
acids for further mutational analysis. 
 
 
Figure 38. Sequence alignment of SBD of Siah1 and Siah2. Unique 26 
aminoacids are highted in grey. Dissimilar amino acids are highlighted by ‘*’. 
Highly Similar amino acids are highlighted by ‘:’ and identical amino acids 
are highlighted by ‘|’.  
 
5.2.5 Mutagenesis of Siah1-2 and Siah2-1 
 Immunoprecipitation studies between SBD of swapped clones, Siah1-2 
and Siah2-1, revealed that both the regions 1-100 and 101-193 are important 
for binding. Out of the 10 residues that differ between Siah1 and Siah2, 6 
amino acid of Siah2 in region 1-100 remain under the Siah2-1construct and 
remaining 4 amino acids of Siah2 in region 101-193 fall under the swapped 
Siah1-2 construct. From the corresponding 6 amino acid positions of Siah1 in 
Siah1-2 clone, three were mutated back to Siah2 (Siah1-2Mut). Similarly from 
the remaining four corresponding Siah1 amino acid position in Siah2-1 clone, 








Figure 39. Representation of mutagenesis and distribution of unique 
amino acids in chimeric forms of Siah. (a) 10 unique amino acids in which 
Siah1 and Siah2 differ are highlighted in diagrammatic representation of SBD 
of Siah1-2 and Siah2-1 (top panel). Three mutated residues of Siah1 in Siah1-
2 clone in region 1-100 to Siah2  and two mutated residues of Siah1 in Siah2-1 
clone in region 101-193 to Siah2 are highlighted (bottom panel). 
Corresponding full length residue number Siah2 are indicated in parentheses. 








5.2.6 Binding of wild type and mutated chimeric SBD's with substrates 
 We proceeded with coimmunoprecipitation studies of the SBDs of 
Siah1-2Mut and Siah2-1Mut with PHD3 and Nrf2. PHD3 is a well-studied 
hypoxia substrate and Nrf2 is a recently identified novel hypoxia substrate 
whose direct binding has been reported.   The results show that Siah2-1Mut 
regains its binding with PHD3 and Nrf2, equivalent to binding levels of WT, 
proving the crucial roles of the amino acids Leu121 (original number 250) and 
Ala160 (289) of Siah2 in binding (Fig 40). On the other hand, Siah1-2Mut 
(E17S, P57S and F98H) did not exhibit the strong binding compared to the 
Siah2 WT and Siah2-1Mut, which verifies the importance of the other three 
residues, His21(150), Pro26(155) and Ala62(191) in binding. Fig 40b also 
shows the specificity of Nrf2 towards the SBD of Siah2 but not that of Siah1. 
The AxVxP motif, is the consensus sequence found in some of the Siah 
substrate proteins (House, Frew et al. 2003; House, Hancock et al. 2006). Both 
Nrf2 and PHD3 have the AXVXP motif at positions 170–174 in Nrf2 
(AQVAP) and at positions 176-180 in PHD3 (ADVEP). Siah2 binds to Nrf2 
through binding motif (Baba, Morimoto et al. 2013). The mutational study 
analysis of Siah isoforms and their chimeric forms with both PHD3 and Nrf2 
are consistent in terms of direct binding, suggesting the importance of the 
identified residues in Siah2.   Since Siah2-1M restore binding equivalent to 
Siah2 WT, we next investigated which of the two mutants (either one or both) 
is critical for this preferential binding. For this point mutants were made and 
the binding with PHD3 was analysed. We observed that Q250L restores 
binding compared to T289A suggesting the importance of Leucine 250 in the 
C terminal region (Fig 41a). Similarly, in the N terminal region of Siah1-2, we 
made remaining 3 mutants and also all 6 mutants to investigate the binding 
with PHD3. But both 3M and 6M only partially restores binding but not 
equivalent to Siah2 WT (Fig. 41b). We next focused on the 10 similar amino 
acid on the N terminal region of which Serine 133 and tyrosine 164 could be 
invovled in hyrogen bonding with its OH group. So we made additional 3 
mutant constructs which include 8M(6+SY), 7M(6+S) and 7M(6+Y). Binding 
of these mutants with PHD3 was analysed. It was observed that 8M  mutant 
increased binding compared to 6M alone (Fig. 41c). This results suggest that 








Figure 40. Siah2-1Mut restores its binding with its substrates. HEK293T cells were transfected with (a) WT FLAG SBD of Siah1, WT 
FLAG SBD of Siah2 , FLAG Siah1-2Mut, FLAG Siah2-1Mut, HA PHD3  or empty vector; (b) WT FLAG SBD of Siah1, WT FLAG SBD of 
Siah2 , Siah1-2Mut, Siah2-1Mut,  Nrf2 or empty vector as indicated on the top of panel, followed by immunoprecipitation (IP) of cell lysates 
with FLAG antibody. Immunoprecipitates were then analyzed for coimunoprecipitates of PHD3 and Nrf2  by Western blotting (WB). Both the 










Figure 41. Analyses of Binding between mutated 2-1 and  1-2 chimeric SBD (a) Binding of wild type and mutated 2-1SBD Chimeric with 
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 Simultaneously, attempts were carried out to solve the structure of 
SBD of Siah2 to analyze whether any significant change in the fold could 
contribute to the differential binding. Even though the crystal structures of 
Siah1 SBD with the peptide EKPAAVVAPITTG from SIP and that for murine 
Siah, in complex with a peptide from phyllopod (discussed in chapter 1.5), are 
known, the Siah2 structure is still important to gain more insights into the 
mechanism of specificity. Hence, we attempted to crystallize the MBP-SBD of 
Siah2. 
 Purified MBP-Siah2-SBD was concentrated up to 10mg/ml and its 
homogeneity was analyzed using dynamic light scattering (DLS). The results 
confirm that MBP-SBD-Siah2-H6 is homogenous but the predicted molecular 
weight was very high suggesting homogeneous aggregation after 
concentrating (Fig 41). 
  Crystallization screening for MBP-SBD-Siah2-6xHis was performed 
by hanging drop vapor diffusion method at room temperature using various 
commercially available Hampton and Emerald biosystems screens. 1 μl of 
purified protein was mixed with 1 μl of the corresponding reservoir solution 
and allowed to equilibrate against 500 μl of the reservoir solution at room 
temperature. Tiny crystals not suitable for diffraction was obtained in wizard 
screen I. Further optimization of the initial conditions is underway.  
 Crystallization trials were also aided by the use of the Mosquito robotic 
crystallization system (TTP Labtech, UK). The robotic screening was carried 
out using hanging drop method in 96 well plates. 0.2 µL of protein sample was 
mixed with 0.2 µL of mother liquor. Crystallization screens with Wizard 






Figure 42. DLS Profile of MBP-SBD of Siah2 at 10mg/ml. 
 
5.3 Discussion 
 There could be various reasons for the varied substrate specificity of 
both Siah1 and Siah2, in spite of their high sequence similarity in terms of 
direct binding. One apparent reason is that one or more unique amino acids 
that is specific for Siah2, favors this selective binding. The other reason could 
be the differences in the conformation of the two proteins. However, this can 
be compared only when the crystal structure of Siah2 is available. We first 
intended to identify the critical residues involved in selective binding of Siah2 
and then we attempted to solve the structure of SBD of Siah2. From our first 
study, we narrowed down 5 critical amino acids, specific for Siah2, that confer 
to substrate specificity. Our results suggest that two regions of the SBD of 
Siah2 are involved in binding and we believe that further validation of these 
residues by using specific Siah1 and Siah2 substrates will provide us with a 
better insight into the unique functions of these proteins. Our study highlights 
the differences in binding between Siah1 and Siah2 with their substrates based 








CHAPTER 6. CONCLUSION AND FUTURE DIRECTIONS 
 
6.1 Conclusion 
6.1.1 Siah2 inhibition as anti-cancer therapy  
 The SBD of Siah1 and Siah2 are highly conserved with 86% sequence 
similarity, making it challenging to design Siah2 specific inhibitor. The N-
terminal regions of Siah1 and Siah2 differ from each other (Della, Senior et al. 
1993), which makes it feasible to design Siah2-specific RING domain 
inhibitors. However, targeting the RING domain does not impair the ability of 
Siah2 to bind to its substrate proteins via the SBD.  Another important issue in 
targeting the RING domain is its similarity among the Ring-finger ligase 
family (Deshaies and Joazeiro 2009) and thus all the inhibitors for E3 ligases 
obtained so far inhibit multiple ligases (Garber 2005). The Siah proteins are 
unique in their SBD, which adopts a pocket and forms the binding site for 
adaptor and substrate containing an AxVxP motif, a consensus motif found in 
most of the Siah binding proteins (House, Frew et al. 2003). Thus, screening 
inhibitors against the Siah2 SBD may lead to identification of specific 
inhibitors that will not affect other ring-finger E3 ligase. Blocking the SBD 
using a peptide inhibitor is capable of reducing tumor growth and metastasis in 
various models (Qi, Nakayama et al. 2008; Shah, Stebbins et al. 2009; Qi, 
Nakayama et al. 2010). So far, menadione is the only available Siah2 specific 
inhibitor, identified from a Meso-Scale-based assay of 2000 compounds 
(Shah, Stebbins et al. 2009). Because of high homology, SBD inhibitors, if 
available, will inhibit both Siah1 and Siah2. In general, the roles of Siah1 and 
Siah 2 are expected to overlap and unique feature for each of the proteins is 
not clear. However based on the current understanding of the role of Siah 
isoforms in cancer, Siah1 is more often described as tumor suppressor and 
Siah2 as an oncogene. 
 Addressing the above facts, our results has contributed the following 
findings, 
1. In the first part of the thesis, SBDD approach was implied and we have 
identified five drug like molecules for SBD of Siah2. These drug-like 
molecules were tested for their efficacy to be potential inhibitors against Siah2 
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by biophysical, biochemical, in vitro and in vivo binding assays, which were 
carried out in the second part of this thesis. The identified compounds were 
experimentally validated for their activity in disrupting the interaction of Siah2 
with its high affinity substrate PHD3 by in vitro and in vivo immuno 
precipitation assays. The thermodynamic properties of the binding between 
SBD and PHD3 or SBD and the compounds were also characterized. From 
these studies, compound 5 is a promising inhibitor among all. The anti-
proliferative and cytotoxic properties of the compounds were also analyzed by 
the MTS assay. 
2. In our initial high throughput virtual screening for compounds against the 
SBD of Siah2, menadione was used as a reference ligand for achieving 
specificity in screening. However the compound specificity for Siah1 and 
Siah2 was not addressed due to the high sequence similarity and the possibility 
of overlapping functions.   Current understanding highlights the controversial 
roles of Siah1 and Siah2 in cancer. The partial activity of the previously 
screened compounds might be due to the lack of specificity. In this regard, the 
third part of the thesis, intends to identify critical amino acids involved in the 
substrate specificity of the SBD of Siah2 with respect to Siah1. With the help 
of chimeric and mutational analysis, a few residues were narrowed down for 
substrate specificity that might help in developing Siah2 specific inhibitors in 
future and could also address the cross-talk between the roles of Siah1 and 
Siah2 in cancer. 
 Overall, our work presents an attempt to translate the mechanistic 
information of Siah2 mediated hypoxic signaling in cancer to structure based 
design of chemical inhibitors which might be useful for anticancer therapy. 
This approach may initiate broad implications in drug discovery efforts 
targeting diverse signaling networks. To more clearly define the mechanism of 
action, it will be a priority in future studies to obtain the structure of Siah2 




6.2 Future directions 
 Based on the experiments and results reported in this thesis, the 
following continuation is proposed. Site directed mutagenesis of the identified 
residues should be performed to further narrow down to specific residues that 
would confer specificity for Siah2 substrates. Using high-throughput virtual 
screening (HTVS) more specific lead compounds can be screened against the 
SBD of Siah2 using the identified residues that show better substrate 
specificity. HTVS from other databases like ZINC, NCI and FDA, which were 
not available during the initial screening, has to be undertaken. In addition, the 
identified compounds should be cross validated against Siah1 using in vitro 
and in vivo studies as the specificity selection of the compounds was not 
implied in our initial screening.  
 To understand the structural and functional role of Siah2 with respect 
to the identified residues, site directed mutation studies could be performed on 
the full length Siah2, to check the affect on activity of the protein to its 
substrate.  In order to further substantiate the findings, another choice would 
have been to use a peptide such as the PHYL peptide that is necessary and 
sufficient for SBD binding to confirm the importance of identified residues. 
Also various Siah substrates (both unique and common for Siah1 and Siah2) 
can be tested  to against this identified unique residues which could help us in 
addressing the cross talk between the roles of Siah1 and Siah2. 
 More crystallization trials should be undertaken to determine the 
structure of SBD of Siah2. As crystal formation of Siah2 wildtype was 
limiting step which could answer most of the hypotheses, it is recommended to 
attempt crystalization trails with mutated Siah2 residues. This could render a 
better comparative picture of the Siah2 protein scaffold with respect to Siah1. 
Co-crystallization of the SBD-inhibitor complex along with apo structure, will 
provide more insights in understanding the interactions between them.  
 Their structural backbone of the inhibitors could serve as building 
blocks in designing better drug-like molecules targeting E3 ligases in cancer 
therapy. Further side chain modification, with the help of medicinal and 
combinatorial chemistry can be undertaken to increase the solubility of the 
inhibitors (Fig. 42). Further screens with different bio-relevant buffer systems, 
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termed as pH proﬁling will allow the detection of a potential counter ion 
exchange and formation of more stable/less-soluble salts of a molecule that 




Figure 43. Example illustration of steps involved in combinatorial 
chemistry based design of ligands. An example of a drug molecule from a 
database is presented in the above figure. Using combinatorial chemistry, 
where the backbone scaffold of the drug molecules has been slightly modified 









































































































A2.1 Purification of PHD3 by refolding 
PHD3 was initially cloned in the pETM vector with N terminal His tag. 
It was expressed as an insoluble protein in E. coli (BL21). The proteins in the 
inclusion bodies was denatured using 6 M GnHCL. The denatured protein was 
first purified with the Ni-NTA resin and then refolded by dialysis. Beyond 2 
M GnHCL, the protein tends to precipitate completely. Hence dialysis was 
stopped at 1.5M GnHCL and then purified by gel filtration using an S75 
column with 0.5M GnHCL. 
Fig. 43a shows the gel filtration results of refolded PHD3. Most of the 
refolded protein got aggregated. Fig. 43b shows the presence of the PHD3 
protein in the gel filtration fractions (mostly in the aggregates) and the protein 
size by SDS-PAGE. As the refolding was not successful, purification of MBP-














Figure 44. Purification of PHD3-His by refolding. (a) The gel filtration 
profile of Phd3 with His tag when loaded onto a size exclusion column. (b) 
SDS-PAGE gel showing the FPLC fractions of the refolded protein with 0.5 M 
GnHCL  run on an S200 gel filtration column. Lanes 1-7 are aggregates. 
 
 
A2.2 MS-MS Analysis of SBD of Siah2 and PHD3 
 For MS/MS analysis, sample digestion, desalting and concentration 
steps were carried out by using the Montage® In-Gel digestion Kits (Millipore 
Corp.) Protein spots were analyzed using an Applied Biosystems 4700 
Proteomics Analyzer MALDI-TOF/TOF (Applied Biosystems, Framigham, 
MA, USA). Data processing and interpretation was carried out using the GPS 
Explorer Software (Applied Biosystems) and database searching was achieved 
by using the MASCOT program (Matrix Science Ltd., London, UK). The 
NCBI database was used for combined MS and MS/MS search. Samples for 













Figure 45. Identification of MBP-SBD of Siah2 and MBP-PHD3 by 
peptide mass fingerprint. The peptide mass fingerprint of peak from gel-





A3.1 IC50 and affinity  
 In biochemical assays, the dissociation constant Kd is termed as the 
inhibition constant Ki. It is important to be aware that data from inhibition is 
often not reported as Ki (or, equivalently, Kd), but instead as the IC50, the 
concentration of a ligand that reduces particular activity by 50%. The 
difference between IC50 and Ki results from the fact, that in a biochemical 
binding assay of a competitive inhibitor, the inhibitor is not the only molecule 
trying to bind the target but also competing with the substrate, so the 
concentration of the ligand needed to reduce the activity by 50% depends on 
the concentration of substrate and how tightly it binds the enzyme. IC50 is not 
a direct indicator of affinity although the two can be related at least for 
competitive agonists and antagonists by the Cheng-Prusoff equation (Cheng 
and Prusoff 1973). In general, then, the IC50 is expected to be greater than Ki 
(the Cheng-Prusoff equation). IC50 is not a direct indicator of affinity, nor is 
Kd/Ki a direct indicator of inhibition. However, the two can be related using 
the Cheng-Prusoff equation:  
 
    
    
   
   
   
 
where Ki is the binding affinity of the inhibitor, IC50 is the functional strength 
of the inhibitor, [S] is substrate concentration and Km is the concentration of 
substrate at which enzyme activity is at half maximal (but is frequently 
confused with substrate affinity for the enzyme, which it is not). Whereas the 
IC50 value for a compound may vary between experiments depending on 
experimental conditions, the Ki is an absolute value. An ITC assay tends to 
require a larger quantity of sample than an enzyme inhibition assays. 
However, ITC has the advantage of not requiring the development of a 
specialized substrate whose reaction can  be detected.  The natural heat release 
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